9805760-7

1805

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 239/42, 239/46, 401/04, 403/04, 405/04, A61K 31/505 — A1

(11) International Publication Number: WO 97/44326

(43) International Publication Date: 27 November 1997 (27.11.97)

(21) International Application Number: PCT/EP97/02454

(22) International Filing Date: 14 May 1997 (14.05.97)

(30) Priority Data:

60/018,218	23 May 1996 (23.05.96)	US
60/040,577	10 March 1997 (10.03.97)	US

(71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH-4070 Basle (CH).

(72) Inventors: BERGER, Jacob; 12135 Dawn Lane, Los Altos Hills, CA 94022 (US). FLIPPIN, Lee, Allen; 17659 Skyline Boulevard, Woodside, CA 94062 (US). GREENHOUSE, Robert; 7173 Arbeau Drive, Newark, CA 94560 (US). JAIME-FIGUEROA, Saul; 4907 Knowlson Terrace, Fremont, CA 94555 (US). LIU, Yanzhou; 3154 Mauricia Avenue, Santa Clara, CA 95051 (US). MILLER, Aubry, Kem; 448 Cypress Avenue, Half Moon Bay, CA 94019 (US). PUTMAN, David, George; 18693 McFarland Avenue, Saratoga, CA 95070 (US). WEINHARDT, Klaus, Kurt; 1042 Colorado Avenue, Palo Alto, CA 94303 (US). ZHAO, Shu-Hai; 426 Ositos Avenue, Sunnyvale, CA 94086 (US).

(74) Agent: BRAUN, Axel; Grenzacherstrasse 124, CH-4070 Basle (CH).

(81) Designated States: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, TR, YU, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.

(54) Title: ARYL PYRIMIDINE DERIVATIVES

(57) Abstract

The present invention is directed to pyrimidine derivatives, and pharmaceutically acceptable salts and *N*-oxides thereof, which exhibit useful pharmacological properties, in particular use as selective $5HT_{2B}$-antagonists, their preparation, pharmaceutical compositions comprising them and their use in the treatment of various diseases, especially migraine. The invention is also directed to formulations and methods for treatment.

THIS SHEET HAS BEEN REPLACED

ARYL PYRIMIDINE DERIVATIVES

The present invention relates to aryl pyrimidine derivatives, and pharmaceutically acceptable salts and N-oxides thereof, which exhibit useful pharmacological properties, including utility as selective $5HT_{2B}$-antagonists. The invention is also directed to formulations thereof and their use for the treatment of diseases.

Serotonin, a neurotransmitter with mixed and complex pharmacological characteristics, was first discovered in 1948, and subsequently has been the subject of substantial research. Serotonin, also referred to as 5-hydroxy-tryptamine (5-HT), acts both centrally and peripherally on discrete 5-HT receptors. Currently, fourteen subtypes of serotonin receptor are recognized and delineated into seven familes, $5\text{-}HT_1$ to $5\text{-}HT_7$. Within the $5\text{-}HT_2$ family, $5\text{-}HT_{2A}$, $5\text{-}HT_{2B}$ and $5\text{-}HT_{2C}$ subtypes are known to exist. These subtypes share sequence homology and display similarities in their specificity for a wide range of ligands. The nomenclature and classification of 5-HT receptors has been reviewed recently by Martin and Humphrey, *Neuropharm.*, **33**, 261-273 (1994) and Hoyer *et al.*, *Pharm. Rev.*, **46**, 157-203 (1994) and Hoyer et al., Pharm. Rev., 46, 157-203 (1994).

$5\text{-}HT_{2B}$ receptors, initially termed $5\text{-}HT_{2F}$ or serotonin-like receptor, were first characterized in rat isolated stomach fundus [Clineschmidt *et al.* (1985), *J. Pharmacol. Exp. Ther.*, **235**, 696-708; Cohen and Wittenauer, (1987), *J. Cardiovasc. Pharmacol.*, **10**, 176-181].

This Sheet Has Been Replaced

The 5-HT_{2C} receptor, first characterized as a 5-HT_{1C} subtype [Pazos *et al.* (1984), *Eur. J. Pharmacol.*, **106**, 539-546] and subsequently recognized as belonging to the 5-HT_2 receptor family [Pritchett *et al.* (1988), *EMBO J.*, **7**, 4135-4140], is widely distributed in the human brain [Pazos *et al.* (1987), *Neuroscience*, **21**, 97-122]. Current evidence strongly supports a therapeutic role for 5-HT_{2C} receptor antagonists in treating anxiety (*e.g.*, generalized anxiety disorder, panic disorder and obsessive compulsive disorder), alcoholism and addiction to other drugs of abuse, depression, migraine, sleep disorders, feeding disorders (*e.g.*, anorexia nervosa) and priapism [Kennett (1993), *Curr. Opin. Invest. Drugs*, **2**, 317-362]. Because of the similarities in the pharmacology of ligand interactions at 5-HT_{2C} and 5-HT_{2B} receptors many of the therapeutic targets that have been proposed for 5-HT_{2C} receptor antagonists are also targets for 5-HT_{2B} receptor antagonists. In particular, several clinical observations suggest a therapeutic role for 5-HT_{2B} receptor antagonists in the prevention of migraine, in that mobilization of 5-HT into the plasma may be a precipitating factor in migraine. Additionally, non-selective 5-HT_{2B} receptor agonists provoke migraine attacks in susceptible individuals, and non-selective 5-HT_{2B} receptor antagonists are effective in preventing the onset of migraine [Kalkman (1994), *Life Sciences*, **54**, 641-644].


Thus, it is clear that selective 5-HT_{2B} receptor antagonists will offer distinct therapeutic advantages collectively in efficacy, rapidity of onset and absence of side effects. In addition, such agents are expected to be useful in the treatment of hypertension [Watts *et al.*, *J. Pharm. Exp. Ther.*, **277**, 1056-1059 (1995)].

Numerous aryl substituted pyrimidine compounds have been exemplified in the chemical and patent literature. For example, Budesinsky *et al.*, *Collection Czechoslav. Chem.*

THIS SHEET HAS BEEN REPLACED

Commun., **26**, 2865-2870 (1961), disclose 2-amino-6-methyl-4-(naphth-1-yl)-pyrimidine as an intermediate useful in the preparation of antibacterial compounds. Other pyrimidine derivatives are described in Mariella *et al.*, *J. Org. Chem.*, **25**, 647-648 (1960); Zagulyaeva *et al.*, *Izv. Sib. Otd. Akad. Nauk SSSR, Ser. Khim. Nauk*, **4**, 27-31 (1990); Essawy *et al.*, *Egypt. J. Chem.*, **37**(4), 423-31 (1994); U.S. Patents Nos. 4,543,248, 4,619,933, 4,665,077, 5,002,951, 5,147,876 and 5,223,505, and European Patent Publication No. [EP] 459 830.

One aspect of the invention concerns compounds represented by formula I:



I

wherein:

R^1 is hydrogen, alkyl, hydroxyalkyl, cycloalkyl, cycloalkyl lower alkyl, alkenyl, lower thioalkoxy, halo, fluoroalkyl, optionally substituted phenyl, optionally substituted phenyl lower alkyl, $-NR^6R^7$, $-CO_2R^8$, or $-O(CH_2)_nR^9$, in which

n is 1, 2, or 3;

R^6 and R^7 are independently hydrogen or lower alkyl;

R^8 is hydrogen or lower alkyl; and

R^9 is hydrogen, lower alkyl, hydroxy, hydroxy lower alkyl, lower alkenyl, or lower alkoxy;

R^2 is hydrogen, lower alkyl, lower alkoxy, halo, or lower fluoroalkyl;

R^3 is optionally substituted aryl;

R^4 is hydrogen, lower alkyl, optionally substituted phenyl-lower alkyl, hydroxy lower alkyl, acyl, $-(CH_2)_mNR^6R^7$, or $-SO_2R^{10}$; in which

This Sheet Has Been Replaced

THIS SHEET HAS BEEN REPLACED

m is an integer of 1-6;
and
R^{10} is lower alkyl; and

R^5 is hydrogen or lower alkyl;

provided that:

when R^3 is naphthyl, pyridyl, thienyl, indol-1-yl, 2,3-dihydroindol-1-yl, or furanyl, and R^2, R^4 and R^5 are all hydrogen, R^1 is not methyl;

when R^3 is phenyl or naphthyl, R^1 is not $-NR^6R^7$;

when R^3 is naphthyl, R^1 is not phenyl; and

when R^3 is 1,2,3,4-tetrahydroquinolinyl, R^4 and R^5 are hydrogen;

and the pharmaceutically acceptable salts and N-oxides thereof.

In another aspect, the invention relates to pharmaceutical compositions containing a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or N-oxide thereof, in admixture with one or more pharmaceutically acceptable, non-toxic carriers.

In yet another aspect, the invention relates to a method for treating a mammal having a disease state which is alleviable by treatment with a $5HT_{2B}$ antagonist, by administering to a mammal in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or N-oxide thereof.

The use of a compound of formula I, a pharmaceutically acceptable salt or N-oxide thereof for the preparation of a medicament for the treatment of a disease state which is alleviable by treatment with a $5HT_{2B}$ antagonist is a further object of the present invention.

This Sheet Has Been Replaced



The following definitions are used throughout the description of the present invention:

"Alkyl" means a branched or unbranched saturated hydrocarbon chain containing 1 to 12 carbon atoms, such as methyl, ethyl, propyl, tert-butyl, n-hexyl, n-octyl, n-dodecyl, and the like.

"Alkenyl" refers to an unsaturated monovalent hydrocarbon radical of 1 to 12 carbon atoms. This term is further exemplified by such radicals as vinyl, prop-2-enyl, pent-3-enyl, hex-5-enyl, oct-2-enyl, and the like.

"Cycloalkyl" means a monovalent saturated carbocyclic radical containing no unsaturation and having from three to eight carbon atoms, *e.g.*, cyclopropyl, 2-methylcyclopropyl, cyclobutyl, 3-ethylcyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl.

"Lower alkyl" means a branched or unbranched saturated hydrocarbon chain containing 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, tert-butyl, butyl, n-hexyl and the like, unless otherwise indicated.

"Lower alkenyl" refers to an unsaturated monovalent hydrocarbon radical of one to six carbon atoms. This term is further exemplified by such radicals as vinyl, prop-2-enyl, pent-3-enyl, and hex-5-enyl.

"Cycloalkyl lower alkyl" as defined herein means cycloalkyl as defined above attached to a lower alkyl radical as defined above, for example *e.g.*, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl, cyclooctylmethyl, and the like.

"Phenyl lower alkyl" means phenyl attached to a lower alkyl radical as defined above, for example phenylmethyl (benzyl), phenylethyl, phenylpropyl, and the like.

"Fluoroalkyl" means alkyl as defined above substituted by 1 to 5 fluorine atoms in any position, for example trifluoromethyl, pentafluoroethyl, 1,1,1-trifluoro-n-propyl, 1-fluoro-n-butyl, 1,2-difluoro-3-methylpentane, 1-fluoro-octane, and the like.

"Lower fluoroalkyl" means lower alkyl as defined above substituted by 1 to 5 fluorine atoms in any position, for example trifluoromethyl, pentafluoroethyl, 1,1,1-trifluoro-n-propyl, 1-fluoro-n-butyl, 1,2-difluoro-3-methylpentane, and the like.

"Acyl" refers to the group -C(O)-R', where R' is lower alkyl as herein defined.


"Lower alkoxy" means the group -O-R' wherein R' is lower alkyl as herein defined. Likewise, "lower thioalkoxy" denotes the group -S-R'.

"Hydroxyalkyl" means the group alkyl as defined above substituted by 1, 2 or 3 hydroxy groups, for example hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 1-hydroxyisopropyl, 2-hydroxyisopropyl, 1,2-dihydroxyisopropyl, 1-hydroxybutyl, 1,3-dihydroxybutyl, and the like. Similarly, "hydroxy lower alkyl" means the group lower alkyl as defined above substituted by 1, 2 or 3 hydroxy groups.


"Halo" denotes fluoro, chloro, bromo, or iodo, unless otherwise indicated.

"Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, "optionally substituted phenyl" or "optionally substituted aryl" means that phenyl or aryl may or may not be substituted with a substituent selected from the group consisting of lower alkyl, lower alkoxy, hydroxy, nitro, lower fluoroalkyl, and halo, and encompasses unsubstituted phenyl and unsubstituted aryl and all possible isomeric phenyl and aryl radicals that are mono, di or trisubstituted.


The term "aryl" as used herein means a monocyclic aromatic ring, or a 9 to 14 membered bicyclic or tricyclic ring system in which at least one ring is aromatic in nature, and includes carbocycles, and heterocycles having one or two heteroatoms chosen from nitrogen, oxygen, and sulfur. Examples of aryl groups include, but are not limited to, phenyl, thiophene, naphthalene, anthracene, phenanthrene, quinoline, isoquinoline, 1,2,3,4-tetrahydro-quinoline, indole, 2,3-dihydroindole, 1H-benzo[b]azepine, 2,3,4,5-tetrahydro-1H-benzo[b]azepine, 2H-benzo[1,4]oxazine, 3,4-dihydro-2H-benzo[1,4]oxazine, 1H,3H-benzo[de]iso-chromene, 6,7,8,9-tetrahydro-5-oxa-9-benzocycloheptane, 2,3-dihydro-1,4-benzodioxane, and the like. More specifically, the term aryl includes structures of the formula:




e.g., naphth-1-yl and naphth-2-yl, and derivatives thereof;




e.g., quinolin-2-yl, quinolin-4-yl, quinolin-8-yl, and the like, and derivatives thereof;




e.g., isoquinolin-1-yl, isoquinolin-4-yl, isoquinolin-8-yl, and the like, and derivatives thereof;




e.g., 1,2,3,4-tetrahydroquinolin-1-yl, 1,2,3,4-tetrahydroquinolin-5-yl, and derivatives thereof;




e.g., 3,4-dihydro-2H-benzo[1,4]oxazin-1-yl, 3,4-dihydro-2H-benzo[1,4]oxazin-5-yl, and derivatives thereof;




where the dotted line represents an optional double bond, *e.g.*, indol-1-yl, 1H-indol-4-yl, 2,3-dihydroindol-1-yl, and derivatives thereof;



e.g., 2,3,4,5-tetrahydro-1H-benzo[b]azepine, and derivatives thereof;



e.g., 7,8,-dihydro-6H-5-oxa-9-aza-benzocyclohepten-9-yl, 7,8,-dihydro-6H-5-oxa-9-aza-benzocyclohepten-4-yl, and derivatives thereof;



e.g., benzo-1,4-dioxane, and derivatives thereof.

The terms "inert organic solvent" or "inert solvent" mean a solvent inert under the conditions of the reaction being described in conjunction therewith [including, for example, benzene, toluene, acetonitrile, tetrahydrofuran ("THF"), dimethylformamide ("DMF"), chloroform ("$CHCl_3$"), methylene chloride (or dichloromethane or "CH_2Cl_2"), diethyl ether, ethyl acetate, acetone, methylethyl ketone, methanol, ethanol, propanol, isopropanol, tert-butanol, dioxane, pyridine, and the like]. Unless specified to the contrary, the solvents used in the reactions of the present invention are inert solvents.

"Pharmaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.

"N-oxide" refers to the stable amine oxide formed at one of the pyrimidine nitrogen atoms.

The term "treatment" as used herein covers any treatment of a disease in a mammal, particularly a human, and includes:

(i) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it;

(ii) inhibiting the disease, *i.e.*, arresting its development; or


(iii) relieving the disease, *i.e.*, causing regression of the disease.

The term "therapeutically effective amount" refers to that amount of a compound of formula I that is sufficient to effect treatment, as defined above, when administered to a mammal in need of such treatment. The therapeutically effective amount will vary depending on the subject and disease state being treated, the severity of the affliction

and the manner of administration, and may be determined routinely by one of ordinary skill in the art.

The term "disease state which is alleviable by treatment with a $5HT_{2B}$ antagonist" as used herein is intended to cover all disease states which are generally acknowledged in the art to be usefully treated with compounds having affinity for $5HT_{2B}$ receptors in general, and those disease states which have been found to be usefully treated by the specific compounds of our invention, the compounds of formula I. Such disease states include, but are not limited to, anxiety (*e.g.*, generalized anxiety disorder, panic disorder and obsessive compulsive disorder), alcoholism and addiction to other drugs of abuse, depression, migraine, hypertension, sleep disorders, feeding disorders (*e.g.*, anorexia nervosa) and priapism.

The compounds of formula I, illustrated below, will be named using the indicated numbering system:



A compound of formula I wherein R^1 is isopropyl, R^2, R^4 and R^5 are hydrogen, and R^3 is 1-naphthyl, is named:

2-amino-6-isopropyl-4-(naphth-1-yl)-pyrimidine.

A compound of formula I wherein R^1 is isopropyl, R^2, R^4 and R^5 are hydrogen, and R^3 is 1H-indol-4-yl, is named:

2-amino-4-(1H-indol-4-yl)-6-isopropylpyrimidine.

A compound of formula I wherein R^1 is methyl, R^2 and R^4 are hydrogen, R^5 is methyl, and R^3 is 1,2,3,4-tetrahydroquinolin-1-yl, is named:

6-methyl-2-(methylamino)-4-(1,2,3,4-tetrahydroquinolin-1-yl)-pyrimidine.

A 1-N-oxide of a compound of formula I wherein R^1 is chloro, R^2 is methyl, R^4 and R^5 are hydrogen, and R^3 is 4-methoxyphenyl, is named:

2-amino-6-chloro-4-(4-methoxyphenyl)-5-methyl-pyrimidine-1-N-oxide.

Among the family of compounds of the present invention, one preferred category includes the compounds of formula I in which R^4 and R^5 are hydrogen or lower alkyl. Within this category a preferred group includes the compounds where R^1 is lower alkyl, fluoroalkyl or hydroxyalkyl and R^3 is optionally substituted aryl, especially where R^3 is optionally substituted 1-naphthyl or indol-4-yl, or a pharmaceutically accetable salt or N-oxide thereof.

Specifically preferred compounds are:

2-amino-4-(2-methylnaphth-1-yl)-6-methylpyrimidine;
2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine
2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-1-N-oxide;
2-amino-4-(4-fluoronaphth-1-yl)-6-(2-methylpropyl)-pyrimidine;
2-amino-6-(tert-butyl)-4-(4-fluoronaphth-1-yl)-pyrimidine;
2-amino-4-(2-methylnaphth-1-yl)-6-methylpyrimidine;
2-amino-4-(1H-indol-4-yl)-6-methylpyrimidine;

2-amino-4-(4-fluoronaphth-1-yl)-6-(1-fluoro-1-methyl-ethyl)-pyrimidine; and

2-amino-4-(4-fluoronaphth-1-yl)-6-(1-hydroxy-1-methyl-ethyl)-pyrimidine;

2-amino-4-(4,6-difluoronaphth-1-yl)-6-(1-fluoro-1-methylethyl)-pyrimidine;

2-methylamino-4-(4-fluoronaphth-1-yl)-6-isopropyl-pyrimidine;


2-amino-4-(4-fluoronaphth-1-yl)-6-(2-methylpropyl)-pyrimidine.

A further preferred group of compounds of the present invention are compounds of formula I in which R^4 and R^5 are hydrogen or lower alkyl, R^1 is lower alkyl and R^3 is optionally substituted indole, e.g. 2-amino-4-(1H-indol-4-yl)-6-methylpyrimidine or a pharmaceutically acceptable salt or N-oxide thereof.

The following methods can be used for the preparation of compounds of formula I:

One such method starts with intermediates of formula (4), the preparation of which is shown in Reaction Scheme I below.

REACTION SCHEME I



where R is lower alkyl, and R^1 and R^2 are as defined with respect to formula I and R^4 and R^5 are hydrogen or lower alkyl.


The starting ketoester of formula (1) may be obtained commercially, for example from Aldrich Chemical Co., Inc., or may be prepared according to methods well known in the art. The compounds of formula (2) are commercially available, or may be prepared according to methods well known in the art.

To prepare compounds of formula (3), a ketoester of formula (1) is treated with an excess of a guanidine derivative of formula (2) in a protic solvent, preferably ethanol, at reflux temperature for about 6-24 hours, preferably about 16 hours. The product of formula (3), a 2-amino-4-hydroxypyrimidine derivative, is isolated by conventional means, and preferably reacted in the next step with no further purification.

The 2-amino-4-hydroxypyrimidine derivative of formula (3) is converted to the corresponding 4-chloro compound of formula (4) by reacting a compound of formula (3) with a chlorinating agent, preferably phosphorous oxychloride, preferably in the absence of solvent. The reaction is conducted at reflux temperature for about 30 minutes to 8 hours, preferably about 2 hours. The product of formula (4), a 2-amino-4-chloropyrimidine derivative, is isolated by conventional means, and is preferably recrystallized before further reaction.

One method of converting a compound of formula (4) to a compound of formula I is shown below in reaction scheme II.

REACTION SCHEME II:




(4) (5) I

where R^1, R^2 and R^3 are as defined with respect to formula I and R^4 and R^5 are hydrogen or lower alkyl.

A 2-amino-4-chloropyrimidine derivative of formula (4) is reacted with a boronic acid derivative of formula (5) in an aqueous solvent, preferably a mixture of ethanol, water and dimethoxyethane, containing a palladium catalyst, preferably palladium tetrakistriphenylphosphine, and an inorganic base, preferably sodium carbonate. The reaction is preferably carried out at the reflux temperature of the solvent, preferably about 80-90°C, for about 5-30 hours, preferably about 14 hours. The product of formula I is isolated by conventional means, and preferably purified by recrystallization.

An alternative method of converting a compound of formula (4) to a compound of formula I is shown below in Reaction Scheme III.

REACTION SCHEME III:




where R is lower alkyl, R^1, R^2 and R^3 are as defined with respect to formula I and R^4 and R^5 are hydrogen or lower alkyl.

The bromoaryl derivative of formula (6) is reacted with a strong base, for example a lower alkyl lithium, preferably n-butyl lithium. The reaction is carried out in an ethereal solvent (for example, diethyl ether, dimethoxyethane, dioxane or tetrahydrofuran, preferably tetrahydrofuran), at a temperature of about -50 to -150°C, preferably about -95°C, for about 5-30 minutes, after which time about 1 equivalent of a trialkoxyborane, preferably trimethoxyborane, is added, and the mixture allowed to warm to room temperature. The product of formula (7), a dimethoxyborane complex, is isolated by removal of solvent, and used in the next reaction with no further purification.


A 2-amino-4-chloropyrimidine derivative of formula (4) is reacted with the boron complex of formula (7) obtained above in an inert solvent, preferably an aromatic solvent, most preferably toluene, containing a palladium catalyst, preferably palladium tetrakistriphenylphosphine, and an aqueous inorganic base, preferably sodium carbonate/water. The reaction is preferably carried out at the reflux temperature of the solvent, preferably about 80-90°C, for about 10 minutes to 10 hours, preferably about 1 hour. The product of formula I is isolated and purified by conventional means, preferably purified by chromatography.

An alternative method is available for converting a compound of formula (4) to a compound of formula I, in which R^3 is a bicyclic ring system containing N as the point of attachment to the pyrimidine nucleus, *i.e.*, R^3 is represented as:



in which n is 0, 1 or 2, Y is CH_2, O, S or NH, and the rings are optionally substituted as defined above. This method is shown below in Reaction Scheme IV.

REACTION SCHEME IV:



(8) (4) I


in which n is 0, 1 or 2, Y is CH_2, O, S or NH, and R^1, R^2, R^4 and R^5 are as defined with respect to formula I.

A 2-amino-4-chloropyrimidine derivative of formula (4) is reacted with the compound of formula (8) in a mixture of water and a strong acid, preferably sulfuric acid, as a solvent. The reaction is preferably carried out at a temperature of about 100°C, for about 20 minutes to 10 hours, preferably about 2 hours. The product of formula I is isolated by conventional means, and preferably purified by recrystallization.


Alternatively, the compounds of formula (4) and (8) are reacted together in a polar solvent, preferably dimethylformamide. The reaction is preferably carried out at a temperature of about 70-90°C, for about 12-72 hours, preferably about 24 hours. The product of formula I is isolated by conventional means, and preferably purified by chromatography.

Compounds of formula I can also be prepared starting from acylaryl derivatives of formula (9), as shown below in Reaction Scheme V.

REACTION SCHEME V:



(9) (10) (11)



(2) I

where R is lower alkyl, R^4 and R^5 are hydrogen or lower alkyl, and R^1, R^2 and R^3 are as defined with respect to formula I.

An acyl aryl derivative of formula (9) may be obtained commercially, for example from Aldrich Chemical Co., Inc., or may be prepared according to methods well known in the art, for example, Friedel-Crafts reaction. In general, an aryl derivative of formula R^3H is reacted with a carboxylic acid derivative, preferably acetic anhydride in the presence of Lewis acid, for example aluminum chloride. The reaction is carried out at a temperature of about -20° to 20°C, preferably 0°C for about 5 minutes to 3 hours, preferably 20 minutes. The acylaryl derivative product of formula (9) is isolated by conventional means, and preferably purified by chromatography.


An acylaryl derivative of formula (9) is reacted with a large excess of an ester of formula (10) in the presence of a strong base, preferably sodium hydride. The reaction is preferably carried out at a temperature of about 80°C, until the compound of formula (9) is consumed. The dione of formula (11) is isolated by conventional means, and preferably purified by chromatography.

Preparation of Compounds of Formula I


The dione of formula (11) is reacted with the compound of formula (2), preferably in the absence of solvent. The reaction is carried out at a temperature of about 100-180°C, preferably at about 150°C, for about 1-10 hours, preferably about 5 hours. The product of formula I is isolated by conventional means, and preferably purified by chromatography.

An alternative method of preparation of compounds of formula I where R^1 is hydrogen from acylaryl derivatives of formula (9) is shown below in Reaction Scheme VI.

REACTION SCHEME VI:



(9) (13)



(13) (2) I


where R^4 and R^5 are hydrogen or lower alkyl, and R^2 and R^3 are as defined with respect to formula I.

An acylaryl derivative of formula (9) is reacted with tert-butyloxybis(dimethylamino)methane (Bredereck's reagent) in a protic solvent, preferably ethanol. The reaction is preferably carried out at a temperature of about 80°C, for about 12 hours to 5 days, preferably about 2 days. The compound of formula (13) is isolated by conventional means, and preferably used in the next reaction with no further purification.


The enone of formula (13) is reacted with the compound of formula (2), preferably in the absence of solvent. The reaction is carried out at a temperature of about 100-180°C, preferably at about 120°C, for about 5-24 hours, preferably about 14 hours. The product of formula I is isolated by conventional means, and preferably purified by recrystallization.

Another method of preparation of compounds of formula I is from intermediates of formula (16), the preparation of which is shown in Reaction Scheme VII below.

REACTION SCHEME VII:



(1) (14) (15)



(15) (16)

where R is lower alkyl, and R^1, and R^2 are as defined with respect to formula I.

The starting ketoester of formula (1) may be obtained commercialy, for example from Aldrich Chemical Co., Inc., or may be prepared according to methods well known in the art. The compounds of formula (14) are commercially available or may be prepared according to methods well known in the art.


To prepare compounds of formula (15), a ketoester of formula (1) is treated with about 2 molar equivalents of an isothiourea derivative of formula (14) in an aqueous solution containing an excess of an inorganic base, preferably sodium carbonate. The reaction is carried out at a temperature range from about 5°C to 60°C, preferably at about 25°C, for about 10 to 100 hours, preferably 60 hours. The product of formula (15), a 4-hydroxy-2-methylthio-pyrimidine derivative, is isolated by conventional means and

preferably reacted in the next step with no further purification.

The 4-hydroxy-2-methylthiopyrimidine derivative of formula (15) is converted to the corresponding 4-chloro compound of formula (16) under conditions similar to that shown above for the preparation of compounds of formula (4) in Reaction Scheme I. The product of formula (16), a 4-chloro-2-methylthiopyrimidine derivative is isolated by conventional means.

One method of converting a compound of formula (16) to a compound of formula I is shown below in Reaction Scheme VIII.

REACTION SCHEME VIII:



where R^1, R^2 and R^3 are as defined with respect of formula I.

In a first step 1 compounds of formula (17) can be prepared as follows:

A 6-(lower alkyl or lower alkoxy)-2-methylthio-pyrimidine compound of formula (16) in an anhydrous ethereal solvent, preferably tetrahydrofuran, is reacted with an excess of a hindered base, preferably lithium diisopropyl-amide, in an anhydrous ethereal solvent, preferably tetrahydrofuran at a temperature range of about -90°C to 10°C, preferably at about -70°C, for about 30 minutes. An excess of a bromoaryl derivative of formula (6) is added and the reaction mixture allowed to warm to ambient temperature. The product of formula (17), a 2-methylthiopyrimidine compound of formula (17) is then isolated and purified by conventional means, preferably by chromatography.

Alternatively, using the method shown in Reaction Scheme III, a compound of formula (16) can be reacted with a compound of formula (7) to give a compound of formula (17).

In a second step 2 compounds of formula (18) can be prepared as follows:

A 2-methylthiopyrimidine derivative of formula (17) is reacted with about 1-4 molar equivalents, preferably about 2 molar equivalents, of a strong oxidizing agent, for example *meta*-chloroperbenzoic acid. The reaction is carried out in an inert solvent, preferably methylene chloride, in a temperature range from about 0°C to 50°C, preferably about 25°C, for about 1 to 30 hours, preferably about 16 hours. The product of formula (18), a 2-methylsulfonylpyrimidine derivative, is isolated by conventional means.


In a third step 3 compounds of formula I can be prepared as follows:

A 2-methylsulfonylpyrimidine derivative of formula (18) is reacted with an excess of a primary or secondary amine in a suitable solvent, for example, ethanol. The reaction is

carried out in a temperature range of about 10° to 100°C, preferably 45°C, for about 1 to 10 hours, preferably 6 hours. The product, a compound of formula I, is isolated and purified by conventional means.


Miscellaneous routes for the preparation of to compounds of formula I are shown in Reaction Scheme IX below:

REACTION SCHEME IX:




I I

where R^1 is hydroxy where R^1 is chloro



I I

where R^1 is chloro where R^1 is NR^6R^7



I I

where R^1 is chloro where R^1 is hydrogen

where R^4 and R^5 are hydrogen or lower alkyl, and R^2 and R^3 are as defined with respect to formula I.

Compounds of formula I where R^1 is chloro can be made from compounds of formula I where R^1 is hydroxy in the same manner as shown in Reaction Scheme I, step 2, above.


Alternatively, compounds of formula I where R^1 is chloro can be made from compounds of formula (4) where R^1 is chloro (*i.e.*, 4,6-dichloro-pyrimidine derivatives) by reacting the dichloro derivative in the same manner as shown in Reaction Schemes II or III.

A compound of formula I where R^1 is chloro is reacted with a primary or secondary amine of formula R^6R^7NH, where R^6 is hydrogen or lower alkyl and R^7 is lower alkyl, in a high-boiling protic solvent, preferably ethylene glycol. The reaction is preferably carried out at a temperature of about 100°C, for about 12 hours to 5 days, preferably about 2 days. The compound of formula I where R^1 is $-NR^6R^7$ is isolated by conventional means.


A compound of formula I where R^1 is chloro is catalytically reduced with hydrogen in the presence of a palladium or platinum catalyst, preferably palladium on carbon support. The reaction is carried out in a protic solvent, preferably methanol or ethanol, in the presence of a strong base, preferably aqueous sodium hydroxide. The reaction is preferably carried out at a temperature of about 10-40°C, preferably about room temperature, at about 1 atmosphere pressure until reduction is complete, about 1 hour. The compound of formula I where R^1 is hydrogen is isolated by conventional means.

The preparation of compounds of formula I where R^1 is thioalkoxy is shown below in Reaction Scheme X.

REACTION SCHEME X:



(9) (19)



(19) + (2) I

where R^4 and R^5 are hydrogen or lower alkyl, and R^2 and R^3 are as defined with respect to formula I.

An acylaryl derivative of formula (9), which may be obtained commercially, for example from Aldrich Chemical Co., Inc., or may be prepared according to methods well known in the art, is mixed with carbon disulfide in an aprotic solvent, for example diethyl ether, benzene, toluene, preferably diethyl ether, in the presence of a strong base, preferably potassium tert-butyloxide, at a temperature of about 10-12°C. The reaction mixture is allowed to warm to room temperature, then recooled to about 10-12°C, at which point 2 molar equivalents of methyl iodide is added dropwise. The mixture is maintained at a temperature of about 10-80°C, preferably about room temperature, for about 5-24 hours, preferably about 16 hours. The bis-methylsulfanyl compound of formula (19) is


isolated by conventional means, and preferably purified by crystallization.

The compound of formula (19) is reacted with the compound of formula (2) in the presence of a strong base, preferably sodium hydride, in a polar solvent, preferably dimethylformamide. The reaction is carried out at room temperature for about 1 hour, then at about 100-180°C, preferably at about 150°C, for about 1-10 hours, preferably about 5 hours. The product of formula I is isolated by conventional means, and preferably purified by chromatography.

The compound of formula (19) is reacted with the compound of formula (2) in the presence of a strong base, preferably sodium hydride, in a polar solvent, preferably dimethylformamide. The reaction is carried out at room temperature for about 1 hour, then at about 100-180°C, preferably at about 150°C, for about 1-10 hours, preferably about 5 hours. The product of formula I is isolated by conventional means, and preferably purified by chromatography.

The preparation of N-oxides of compounds of formula I is shown below in Reaction Scheme XI.

REACTION SCHEME XI:



I Ia Ib


where R^1, R^2, R^3, R^4 and R^5 are as defined with respect to formula I.

A compound of formula I is reacted with an oxidizing agent, preferably m-chloroperbenzoic acid, in an inert solvent, preferably chloroform or methylene dichloride. The reaction is preferably carried out at a temperature of about 30-60°C, preferably about 40°C, for about 10 minutes to 2 hours, preferably about 30 minutes. The N-oxide of the compound of formula I is isolated by conventional means.

The position of the N-oxidation varies depending upon the steric hindrance of the R^1 group. For example, where R^1 is methyl, N-oxidation occurs almost exclusively at the 1-position (formula Ia). However, as the R^1 group increases in size, increasing amounts of the 3-N-oxide (formula Ib) are seen. For example, where R^1 is tert-butyl, most of the oxidation is directed toward the 3-position. For oxidations where a mixture of N-oxides are obtained, the 1-N-oxides and 3-N-oxides can be separated by chromatography, or by selective crystallization from a suitable solvent, for example from a mixture of ethanol/ether.

The preparation of compounds of formula I where R^1 is hydroxyalkyl or alkenyl from N-oxides of formula I is shown below in Reaction Scheme XII.

REACTION SCHEME XII:



where in formulae Ia and Ib R^1 is alkyl, and in formula I R^1 is hydroxyalkyl or alkenyl, and R^2, R^3, R^4 and R^5 are as with respect to formula I.

An N-oxide of formula I where R^1 is alkyl is reacted with an excess of a carboxylic anhydride preferably trifluoroacetic anhydride, in an inert solvent, preferably methylene chloride. The reaction is carried out at a temperature of about 5 to 60°C, preferably about 25°C, for about 10 to 60 hours, preferably 48 hours. A mixture of compounds of formula I where R^1 is 6-hydroxyalkyl or 6-alkenyl is obtained, and is separated, isolated and purified by conventional means, preferably by chromatography.

The compounds of formula I where R^1, R^2 and R^3 are as defined above, and R^4 and R^5 are hydrogen may be converted to other compounds of formula I by replacing one or both hydrogens of R^4 and R^5 with other groups:

A. For example, a compound of formula I where R^4 is acetyl, may be prepared by reaction with an acylating agent,

preferably acetic anhydride, optionally in the presence of 4-dimethylaminopyridine. The reaction mixture was carried out at a temperature range of 0° to 100°C, for about 4 hours. A diacetyl product is isolated by conventional means, dissolved in a protic solvent, such as methanol, and treated with sodium bicarbonate for about 1 to 24 hours. The resulting monoacetyl product, a compound of formula I, is isolated and purified by conventional means.

B. For example, a compound of formula I where R^4 and R^5 are methanesulfonyl, may be prepared by reaction with triethyl amine and a sulfonylating agent, preferably methanesulfonyl chloride. The reaction was carried out in an inert organic solvent, such as dichloromethane, at a temperature of about 0°, for about 5 minutes to 3 hours, preferably 30 minutes. The resulting bis-methylsulfonyl product, a compound of formula I, is isolated and purified by conventional means.

C. For example, a compound of formula I where R^4 is methanesulfonyl, and R^5 is hydrogen, may be prepared from the bis-methanesulfonyl product previously described above in (B), under basic conditions, preferably sodium hydroxide. The reaction was carried out in a protic organic solvent, such as methanol, at about room temperature for about 30 minutes to 3 hours, preferably 1 hour. The resulting mono-methanesulfonyl product, a compound of formula I, is isolated and purified by conventional means.

D. For example, a compound of formula I where R^4 and R^5 is hydrogen may be prepared by reaction with phenylisocyanate. The reaction was carried out in an inert organic solvent, preferably benzene, at reflux temperature for about 10 to 60 hours, preferably 48 hours. The resulting urea product, a compound of formula I, is isolated and purified by conventional means.

E. For example, a compound of formula I where R^4 is 2-(dimethylamino)imino, and R^5 is hydrogen, may be prepared by reaction with a guanidine derivative, such as 1,1-dimethylguanidine, and following the procedures described in reaction scheme I.

Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography, thick-layer chromatography, preparative low or high-pressure liquid chromatography or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be taken from the preparations and examples. However, other equivalent separation or isolation procedures could, of course, also be used.

The compounds of formula I are basic, and thus may be converted to a corresponding acid addition salt.


The conversion is accomplished by treatment with at least a stoichiometric amount of an appropriate acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. Typically, the free base is dissolved in an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, ethanol or methanol and the like, and the acid added in a similar solvent. The temperature is maintained at 0°-50°C. The resulting salt precipitates

spontaneously or may be brought out of solution with a less polar solvent.

The acid addition salts of the compounds of formula I may be converted to the corresponding free bases by treatment with at least a stoichiometric amount of a suitable base such as sodium or potassium hydroxide, potassium carbonate, sodium bicarbonate, ammonia, and the like.


Compounds of formula I can be prepared as follows:

1. Reacting a compound of the formula:




where R^1 and R^2 are as defined above and R^4 and R^5 are hydrogen or lower alkyl;
with a boronic acid derivative of formula (5), *i.e.*, $R^3B(OH)_2$, where R^3 is as defined with respect to formula I.

2. Alternatively, a process for preparing compounds of formula I comprises:
reacting a compound of the formula:




where R^1 and R^2 are as defined with respect to formula I, and R^4 and R^5 are hydrogen or lower alkyl;
with a boron complex of formula (7), *i.e.*, $R^3B(OCH_3)_2$, where R^3 is as defined with respect to formula I.

3. Alternatively, a process for preparing compounds of formula I comprises:
reacting a compound of the formula:




where R^1 and R^2 are as defined with respect to formula I and R^4 and R^5 are hydrogen or lower alkyl;
with a compound of the formula (8):



where Y and n are as defined above.


4. Alternatively, a process for preparing compounds of formula I comprises:
reacting a compound of the formula:



where R^1, R^2, and R^3 are as defined with respect to formula I;


with a compound of the formula $NH_2C(:NH)NR^4R^5$ (formula (2)), where R_4 and R_5 are as defined with respect to formula I.

5. Alternatively, a process for preparing compounds of formula I comprises:
reacting a compound of the formula:




where R^2 and R^3 are as defined with respect to formula I;
with a compound of the formula $NH_2C(:NH)NR^4R^5$ (formula (2)), where R_4 and R_5 are as defined with respect to formula I.

6. Alternatively, a process for preparing compounds of formula I comprises:
reacting a compound of the formula:



where R^3 is as defined with respect to formula I
with a compound of the formula $NH_2C(:NH)NR^4R^5$ (formula (2)), where R_3 is as defined with respect to formula I.

7. Alternatively, a process for preparing compounds of formula I comprises:
reacting a compound of the formula I where R^1 is chloro:




where R^2 and R^3 are as defined with respect to formula I, and R^4 and R^5 are hydrogen or lower alkyl; with

A) a reducing agent, to give a compound of formula I where R^1 is hydrogen; or

B) a secondary amine of formula HNR^6R^7, where R^6 and R^7 are as defined with respect to formula I, to give a compound of formula I where R^1 is $-NR^6R^7$.

8. Alternatively, a process for preparing compounds of formula I comprises:

reacting a compound of the formula:



where R^1, R^2 and R^3 are as defined with respect to formula I, with a secondary amine of formula HNR^4R^5, where R^4 and R^5 are as defined with respect to formula I, to give a compound of formula I, where R^4 and R^5 are as defined with respect to formula I.

9. Alternatively, a process for preparing compounds of formula I where R^1 is hydroxyalkyl or alkenyl comprises: reacting an N-oxide of a compound of formula I where R^1 is alkyl with a carboxylic anhydride to give a compound of formula I.

10. Alternatively, a process for preparing compounds of formula I comprises:

reacting a compound of formula I with an oxidizing agent to give an N-oxide of a compound of formula I, or:
reacting a compound of formula I with a strong acid to give a pharmaceutically acceptable salt of a compound of formula I.

The compounds of this invention are selective 5-HT_{2B} receptor antagonists. Affinity for the 5-HT_{2B} receptors was demonstrated using an *in vitro* binding assay utilizing cloned 5-HT_{2B} receptors radiolabelled with [^{3}H]-5HT, as shown in Example 17 *infra*. Selectivity for the 5-HT_{2B} receptor was shown by counter screening at 5-HT_{2A} and 5-HT_{2C} receptors (for details see Example 18, *infra*.). Antagonist properties were determined in rat stomach fundus longitudinal muscle (for further details see Example 19, *infra*.).

Accordingly, the compounds of this invention are useful for treating diseases which can be ameliorated by blockade of 5-HT_{2B} receptors. Because of the similarities in the pharmacology of ligand interactions at 5-HT_{2C} and 5-HT_{2B} receptors many of the therapeutic targets that have been proposed for 5-HT_{2C} receptor antagonists are also targets for 5-HT_{2B} receptor antagonists. In particular, several clinical observations suggest a therapeutic role for 5-HT_{2B} receptor antagonists in the prevention of migraine, in that mobilization of 5-HT into the plasma is believed to be a precipitating factor in migraine. Additionally, non-selective 5-HT_{2B} receptor agonists provoke migraine attacks in susceptible individuals, and non-selective 5-HT_{2B} receptor antagonists are effective in preventing the onset of migraine [Kalkman, *Life Sciences*, **54**, 641-644 (1994)].

Clinical and experimental evidence support a therapeutic role for 5-HT_{2C} receptor antagonists in treating anxiety. The 5-HT_{2C} receptor agonist 1-(3-chlorophenyl)-

piperazine (mCPP) when administered to human volunteers causes anxiety [Charney *et al.* (1987), *Psychopharmacology*, **92**, 14-24]. MCPP also produces anxiogenic effects in rat, social interaction (SI) and elevated X-maze models of anxiety, which effects are blocked by non-selective 5-$HT_{2C/2A}$ receptor antagonists but not by selective 5-HT_{2A} receptor antagonists [Kennett *et al.* (1989), *Eur. J. Pharmacol.*, **164**, 445-454 and Kennett (1993), supra]. In addition, non-selective 5-$HT_{2C/2A}$ receptor antagonists by themselves produce anxiolytic effects in the SI and Geller Seifter conflict tests, while selective 5-HT_{2A} receptor antagonists do not share this property. This therapeutic target for 5-HT_{2C} receptor antagonists is equally a target for 5-HT_{2B} receptor antagonists.

Furthermore, mCPP when administered to panic disorder patients or obsessive compulsive disorder patients increases levels of panic and/or anxiety [Charney *et al.* (1987), supra., and Zohar *et al.* (1987), *Arch. Gen. Psychiat.*, **44**, 946-951]. Thus, current evidence support the application of selective 5-HT_{2C} receptor antagonists for treating generalized anxiety disorder, panic disorder and obsessive compulsive disorder. These therapeutic targets for 5-HT_{2C} receptor antagonists are equally targets for 5-HT_{2B} receptor antagonists.

Anxiolytic activity can be determined experimentally by the art-recognized Crawley and Goodwin two-compartment exploratory model [*e.g.*, see Kilfoil *et al.* (1989), *Neuropharmacology*, **28(9)**, 901-905]. In brief, the method measures the extent a compound affects the natural anxiety of mice in a novel, brightly lighted area (for further details see Example 21, *infra.*).

Clinical and experimental evidence support a therapeutic role for selective 5-HT_{2C} receptor antagonists

in treating chemical dependency. The 5-HT_{2C} receptor agonist mCPP induces a craving for alcohol in abstaining alcoholics [Benkelfat *et al.* (1991), *Arch. Gen. Psychiat.*, **48**, 383]. In contrast, the non-selective 5-$HT_{2C/2A}$ receptor antagonist ritanserin reduces alcohol preference in rats [Meert *et al.*, (1991), *Drug Development Res.* **24**, 235-249], while the selective 5-HT_{2A} receptor antagonist ketanserin has no affect on preference for alcohol [Kennett *et al.*, (1992), *J. Psychopharmacol.*, Abstr. A26]. Ritanserin also reduces both cocaine and fentanyl preference in rat models of addiction [Meert *et al.* (1991), *Drug Development Res.* **25**, 39-53 and Meert *et al.*, (1991), *Drug Development Res.* **25**, 55-66]. Clinical studies show that ritanserin decreases alcohol intake in chronic alcoholics [Monti *et al.* (1991), *Lancet.* **337**, 60] and is useful in patients withdrawing from other drugs of abuse [Sadzot *et al.* (1989), *Psychopharmacology*, **98**, 495-499]. Thus, current evidence support the application of selective 5-HT_{2C} receptor antagonists for treating alcoholism and addiction to other drugs of abuse. This therapeutic target for 5-HT_{2C} receptor antagonists is equally a target for 5-HT_{2B} receptor antagonists.

Ameliorating effects of compounds during withdrawal from drugs of abuse can be determined experimentally by the mouse, withdrawal anxiety test, an accepted assay [Carboni *et al.* (1988), *Eur. J. Pharmacol*, **151**, 159-160]. This procedure utilizes the exploratory model described above to measure the extent a compound ameliorates the symptoms of withdrawal that occur after chronically treating with an addictive substance and then abruptly ceasing the treatments (for further details see Example 22, *infra.*).

Clinical evidence support a therapeutic role for selective 5-HT_{2C} receptor antagonists in treating depression. For example, non-selective 5-$HT_{2C/2A}$ receptor

antagonists show clinical efficacy in treating depression [Murphy (1978), *Brit. J. Pharmacol.*, **5**, 81S-85S; Klieser *et al.* (1988), *Pharmacopsychiat.*, **21**, 391-393; and Camara (1991), *Biol. Psychiat.*, **29**, 201A]. Furthermore, experimental results suggest that the mechanism by which conventional antidepressant drugs exert their therapeutic efficacy is through adaptive changes in the serontinergic system [Anderson (1983), *Life Sci*, **32**, 1791-1801]. For example, chronic treatment with monamine oxidase inhibitors reduce mCPP-induced/5-HT_{2C} mediated functional responses in a variety of paradigms. Similar effects are exhibited by selective 5-HT reuptake inhibitors. These findings suggest that treatments which enhance extraneuronal 5-HT levels desensitize 5-HT_{2C} receptor function which in turn causes, or contributes to, antidepressant activity ([Kennett (1993), supra]. This therapeutic target for 5-HT_{2C} receptor antagonists is equally a target for 5-HT_{2B} receptor antagonists.

Clinical evidence support a therapeutic role for 5-HT_{2C} receptor antagonists in treating sleep disorders. The 5-HT_{2C} receptor agonist mCPP when administered to human volunteers reduces total sleep time, sleep efficiency, slow wave sleep (SWS) and rapid eye movement sleep [Lawlor *et al.* (1991), *Biol. Psychiat.*, **29**, 281-286]. In contrast, the non-selective 5-$HT_{2C/2A}$ receptor antagonist ritanserin increases SWS, reduces sleep onset latency and improves subjective sleep quality in healthy volunteers [Idzikowski *et al.* (1986), *Brain Res.*, **378**, 164-168; Idzikowski *et al.* (1987), *Psychopharmacology*, **93**, 416-420; Declerck *et al.* (1987), *Curr. Therap. Res.*, **41**, 427-432; and Adam *et al.* (1989), *Psychopharmacology*, **99**, 219-221]. Thus, given the opposing effects of 5-HT_{2C} receptor stimulation and 5-HT_{2C} receptor antagonism, selective 5-HT_{2C} receptor antagonists could be of particular therapeutic value in treating sleep disorder [Kennett (1993), supra]. This therapeutic target

for 5-HT_{2C} receptor antagonists is equally a target for 5-HT_{2B} receptor antagonists.

Clinical evidence support a therapeutic role for 5-HT_{2C} receptor antagonists in feeding disorders. Non-specific 5-$HT_{2C/2A}$ receptor antagonists are shown to produce increased appetite and weight gain. Thus, there is some clinical evidence to support the application of selective 5-HT_{2C} receptor antagonists for the treatment of anorexia nervosa. This therapeutic target for 5-HT_{2C} receptor antagonists is equally a target for 5-HT_{2B} receptor antagonists.

Experimental evidence support a therapeutic role for 5-HT_{2C} receptor antagonists in treating priapism. MCPP produces penile erections in rats, which effect is blocked by non-selective 5-$HT_{2C/2A}$ receptor antagonists but not by selective 5-HT_{2A} receptor antagonists [Hoyer (1989), In: Fozard J. (ed.) Peripheral actions of 5-HT, Oxford University Press, Oxford, 72-99]. This therapeutic target for 5-HT_{2C} receptor antagonists is equally a target for 5-HT_{2B} receptor antagonists.

In applying the compounds of this invention to treatment of the above conditions, administration of the active compounds and salts described herein can be via any of the accepted modes of administration, including oral, parenteral and otherwise systemic route of administration. Any pharmaceutically acceptable mode of administration can be used, including solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, or the like, preferably in unit dosage forms suitable for single administration of precise dosages, or in sustained or controlled release dosage forms for the prolonged administration of the compound at a predetermined rate. The compositions will typically include a conventional

pharmaceutical carrier or excipient and an active compound of formula I or the pharmaceutically acceptable salts thereof and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, etc.

The amount of active compound administered will of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration and the judgment of the prescribing physician. However, an effective dose for oral, parenteral and otherwise systemic routes of administration is in the range of 0.01-20 mg/kg/day, preferably 0.1-10 mg/kg/day. For an average 70 kg human, this would amount to 0.7-1400 mg per day, or preferably 7-700 mg/day.

One of ordinary skill in the art of treating such diseases will be able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this application, to ascertain a therapeutically effective amount of a compound of formula I for a given disease.

For solid compositions, conventional non-toxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, cellulose, cellulose derivatives, sodium crosscarmellose, starch, magnesium stearate, sodium saccharin, talcum, glucose, sucrose, magnesium carbonate, and the like may be used. The active compound as defined above may be formulated as suppositories using, for example, polyalkylene glycols, acetylated triglycerides and the like, as the carrier. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered

may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see *Remington's Pharmaceutical Sciences*, Mack Publishing Company, Easton, Pennsylvania, 15th Edition, 1975. The composition or formulation to be administered will, in any event, contain a quantity of the active compound(s) in an amount effective to alleviate the symptoms of the subject being treated.

Dosage forms or compositions containing active ingredient (compounds of formula I or its salts) in the range of 0.25 to 95% with the balance made up from non-toxic carrier may be prepared.

For oral administration, a pharmaceutically acceptable non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, cellulose, cellulose derivatives, sodium crosscarmellose, starch, magnesium stearate, sodium saccharin, talcum, glucose, sucrose, magnesium, carbonate, and the like. Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like. Such compositions may contain 1%-95% active ingredient, more preferably 2-50%, most preferably 5-8%.

Parenteral administration is generally characterized by injection, either subcutaneously, intramuscularly or intravenously. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid

forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like. In addition, if desired, the pharmaceutical compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, triethanolamine sodium acetate, etc.

A more recently devised approach for parenteral administration employs the implantation of a slow-release or sustained-release system, such that a constant level of dosage is maintained. See, *e.g.*, U.S. Patent No. 3,710,795.

The percentage of active compound contained in such parental compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject. However, percentages of active ingredient of 0.1% to 10% in solution are employable, and will be higher if the composition is a solid which will be subsequently diluted to the above percentages. Preferably the composition will comprise 0.2-2% of the active agent in solution.

In applying the compounds of the invention to treatment of diseases or disorders of the eye which are associated with an abnormally high intraocular pressure, administration may be achieved by any pharmaceutically acceptable mode of administration which provides adequate local concentrations to provide the desired response. These include direct administration to the eye via drops and controlled release inserts or implants, as well as systemic administration as previously described.

Drops and solutions applied directly to the eye are typically sterilized aqueous solutions containing 0.1% to 10%, most preferably 0.5% to 1% of the active ingredient, along with suitable buffer, stabilizer, and preservative. The total concentration of solutes should be such that, if possible, the resulting solution is isotonic with the lacrimal fluid (though this is not absolutely necessary) and has an equivalent pH in the range of pH 6-8. Typical preservatives are phenyl mercuric acetate, thimerosal, chlorobutanol, and benzalkonium chloride. Typical buffer systems and salts are based on, for example, citrate, borate or phosphate; suitable stabilizers include glycerin and polysorbate 80. The aqueous solutions are formulated simply by dissolving the solutes in a suitable quantity of water, adjusting the pH to about 6.8-8.0, making a final volume adjustment with additional water, and sterilizing the preparation using methods known to those in the art.

The dosage level of the resulting composition will, of course, depend on the concentration of the drops, the condition of the subject and the individual magnitude of responses to treatment. However, a typical ocular composition could be administered at the rate of about 2-10 drops per day per eye of a 0.5% solution of active ingredient.

The compositions of the present invention may also be formulated for administration in any convenient way by analogy with other topical compositions adapted for use in mammals. These compositions may be presented for use in any conventional manner with the aid of any of a wide variety of pharmaceutical carriers or vehicles. For such topical administration, a pharmaceutically acceptable non-toxic formulation can take the form of semisolid, liquid, or solid, such as, for example, gels, creams, lotions, solutions, suspensions, ointments, powders, or the like. As

an example, the active components may be formulated into a gel using ethanol, propylene glycol, propylene carbonate, polyethylene glycols, diisopropyl adipate, glycerol, water, etc., with appropriate gelling agents, such as Carbomers, Klucels, etc. If desired, the formulation may also contain minor amounts of non-toxic auxiliary substances such as preservatives, antioxidants, pH buffering agents, surface active agents, and the like. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in the art; for example, see *Remington's Pharmaceutical Sciences*, Mack Publishing Company, Easton, Pennsylvania, 16th Edition, 1980.

Preferably the pharmaceutical composition is administered in a single unit dosage form for continuous treatment or in a single unit dosage form ad libitum when relief of symptoms is specifically required. Representative pharmaceutical formulations containing a compound of formula I are described in Examples 4-10.

The following preparation and examples illustrate the invention but are not intended to limit its scope.

PREPARATION 1

Preparation of Compounds of Formula (3)

A. Preparation of (3) where R^1 is tert-Butyl and R^2 is Hydrogen

Methyl 4,4-dimethyl-3-oxopentanoate (15.82 g) and guanidine carbonate (20.0 g) were mixed in 80 ml of ethanol, and the solution refluxed for 16 hours. The reaction mixture was concentrated to 50 ml by removal of solvent under reduced pressure, and 20 ml of water was added. The remaining mixture was acidified to pH 5 with acetic acid, affording a white precipitate. The precipitate was collected by filtration, washed with water, and dried in a

vacuum oven to give 2-amino-4-hydroxy-6-tert-butylpyrimidine (12.6 g), m.p. 285-288°C (dec.).

B. Preparation of (3) where R^2 is Hydrogen, varying R^1

Similarly, replacing methyl 4,4-dimethyl-3-oxopentanoate with:

ethyl 3-oxopentanoate;
ethyl 4-methyl-3-oxopentanoate;
ethyl 3-cyclobutyl-3-oxopropionate;
ethyl 3-cyclopentyl-3-oxopropionate;
ethyl 4-methyl-3-oxohexanoate;
ethyl 2-methyl-3-oxobutanoate;
ethyl 3-oxo-4-phenylpentanoate;
ethyl 3-cyclopropyl-3-oxopropionate;
ethyl 2-fluoro-3-oxobutanoate;
ethyl 2-aminocarbonylacetate;
ethyl 4,4,4-trifluoro-3-oxobutanoate; and
ethyl 3-phenyl-3-oxopropionate;

(in some syntheses the methyl ester was used instead of the ethyl ester; both work equally well):

and following the procedures of Preparation 1A above, the following compounds of formula (3) were prepared:

2-amino-6-ethyl-4-hydroxypyrimidine;
2-amino-4-hydroxy-6-isopropylpyrimidine, m.p. 238-241°C;
2-amino-6-cyclobutyl-4-hydroxypyrimidine, m.p. 253-254°C;
2-amino-6-cyclopentyl-4-hydroxypyrimidine, m.p. 237-241°C (dec.);
2-amino-6-(but-2-yl)-4-hydroxypyrimidine, m.p. 195-198°C;
2-amino-5,6-dimethyl-4-hydroxypyrimidine;
2-amino-6-benzyl-4-hydroxypyrimidine;
2-amino-6-cyclopropyl-4-hydroxypyrimidine;
2-amino-5-fluoro-4-hydroxy-6-methylpyrimidine;
2,6-diamino-4-hydroxypyrimidine;

2-amino-4-hydroxy-6-trifluoromethylpyrimidine; and
2-amino-4-hydroxy-6-phenylpyrimidine.

C. Similarly, optionally replacing methyl 4,4-dimethyl-3-oxopentanoate with other compounds of formula (1), and optionally replacing guanidine carbonate with other compounds of formula (2), and following the procedures of Preparation 1A above, other compounds of formula (3) are prepared.

PREPARATION 2

Preparation of Compounds of Formula (4)

A. Preparation of (4) where R^1 is tert-Butyl and R^2 is Hydrogen

2-Amino-4-hydroxy-6-tert-butylpyrimidine (8.35 g) was dissolved in 50 ml of phosphorus oxychloride and the solution refluxed for 2 hours. Excess phosphorus oxychloride was removed under vacuum and the residue dissolved in 100 ml of ethanol. The solution was adjusted to pH 8 with ice-cold concentrated ammonium hydroxide, and solvent removed under reduced pressure. The residue was filtered to give a white solid, which was recrystallized from ethanol-water to give 2-amino-4-chloro-6-tert-butylpyrimidine (3.66 g), m.p. 87.7-88.9°C.

B. Similarly, replacing 2-amino-4-hydroxy-6-tert-butylpyrimidine with other compounds of formula (3) and following the procedures of Preparation 2A above, the following compounds of formula (4) were prepared:

2-amino-4-chloro-6-ethylpyrimidine;
2-amino-4-chloro-6-isopropylpyrimidine, m.p. 94-97°C;
2-amino-4-chloro-6-cyclopropylmethylpyrimidine, m.p. 116.5-120.0°C;
2-amino-4-chloro-6-cyclobutylpyrimidine, m.p. 98-99°C;
2-amino-6-(but-2-yl)-4-chloropyrimidine, m.p. 63-65°C;

2-amino-4-chloro-6-cyclopentylpyrimidine,
m.p. 101.5-103°C.
2-amino-4-chloro-5,6-dimethylpyrimidine;
2-amino-6-benzyl-4-chloropyrimidine;
2-amino-4-chloro-6-cyclopropylpyrimidine;
2-amino-4-chloro-5-fluoro-6-methylpyrimidine;
2,6-diamino-4-chloropyrimidine;
2-amino-4-chloro-6-trifluoromethylpyrimidine; and
2-amino-4-chloro-6-phenylpyrimidine.

C. Similarly, replacing 2-amino-4-hydroxy-6-tert-butyl-pyrimidine with other compounds of formula (3), and following the procedures of Preparation 2A above, other compounds of formula (4) are prepared.

PREPARATION 3

Preparation of Compounds of Formula (9)

A. Preparation of (9) where R^3 is 4,7-Difluoronapth-1-yl and R^2 is Hydrogen

1,6-Difluoronaphthalene (0.164 g, 1.0 mmol) was dissolved in 1,2-dichloroethane (5 ml) and cooled to 0°C. Aluminum trichloride (0.264 g, 2.0 mmol) was added as a solid to the solution. Acetic anhydride (0.1 ml, 1.0 mmol) was added slowly over 20 minutes to the solution while maintaining a temperature of 0°C. The reaction was poured onto ice-cold 10% aqueous hydrochloric acid and extracted with methylene chloride (2 X 10 ml). The organic layer was dried over sodium sulfate, concentrated, and purified by column chromatography to give 1-(4,7-difluoronaphth-1-yl)-ethanone as an oil (0.165 g, 80%).

B. Similarly, replacing 1,6-difluoronaphthalene with other compounds of formula R^3, and following the procedures of

Preparation 3 above, other compounds of formula (9) are prepared.

PREPARATION 4

Preparation of Compounds of Formula (15)

A. Preparation of (15) where R^1 is methyl and R^2 is Hydrogen

S-Methylisothiourea (22.26 g, 160 mmol) was added to a solution of sodium carbonate (16.9 g, 160 mmol) in water (50 ml) and stirred at room temperature until complete dissolution of the *S*-methylisothiourea. Ethyl acetoacetate (10.41 g, 80 mmol) was added to the mixture in one portion. After stirring for 60 hours at room temperature, the reaction was neutralized with acetic acid precipitating a white solid. The solid was collected, washed with water, and dried *in vacuo* to give 4-hydroxy-6-methyl-2-(methylthio)pyrimidine (9.38 g, 75%), m.p. 218-221°C.

B. Preparation of (15) where R^2 is Hydrogen, varying R^1

Similarly, replacing ethyl acetoacetate with ethyl-4-methyl-3-oxopentanoate or methyl-4,4-dimethyl-3-oxopentanoate, and following the procedures of Preparation 4A above, the following compounds of formula (15) were prepared:

4-hydroxy-6-isopropyl-2-(methylthio)pyrimidine; and
6-*tert*-butyl-4-hydroxy-2-(methylthio)pyrimidine.

C. Preparation of (15) where R^2 is Hydrogen, varying R^1

Similarly, replacing ethyl acetoacetate with other compounds of formula (1) and following the procedures of Preparation 4A above, other compounds of formula (15) are prepared.

PREPARATION 5

Preparation of Compounds of Formula (16)

A. Preparation of (16) where R^1 is Methyl and R^2 is Hydrogen

4-Hydroxy-6-methyl-2-(methylthio)pyrimidine (9.20 g, 59 mmol) and phosphorous oxychloride (60 ml) were combined and refluxed for 3 hours. The reaction mixture was cooled to room temperature and poured onto crushed ice. The resultant aqueous mixture was extracted with ethyl acetate; and the organic layer washed with saturated aqueous sodium bicarbonate followed by a water wash, dried over magnesium sulfate, and dried *in vacuo* to give 4-chloro-6-methyl-2-(methylthio)pyrimidine (8.27 g, 80%), m.p. 37-38°C.

B. Similarly, replacing 4-hydroxy-6-methyl-2-(methylthio)-pyrimidine with other compounds of formula (15), and following the procedures of Preparation 5A above, the following compounds of formula (16) were prepared:

4-chloro-6-isopropyl-2-(methylthio)pyrimidine, b.p. 127-128°C @ 0.5 torr; and

6-*tert*-butyl-4-chloro-2-(methylthio)pyrimidine, m.p. 46-48°C.

C. Similarly, replacing 4-hydroxy-6-methyl-2-(methylthio)pyrimidine with other compounds of formula (15) and following the procedures of Preparation 5A above, other compounds of formula (16) are prepared.

PREPARATION 6

Preparation of Compounds of Formula (17)

A. Preparation of (17) where R^1 is Isopropyl, R^2 is Hydrogen, and R^3 is 4-Fluoro-1-naphthyl

A stirred solution of 1-bromo-4-fluoronaphthalene (4.95 g) in 100 ml tetrahydrofuran was cooled to -80°C, stirred and 2.5M n-butyllithium (10 ml) was added dropwise. The mixture was stirred for 30 minutes, then trimethoxyborane (3

ml) added, the mixture stirred for 1 hour, then allowed to warm to room temperature, and solvent removed under reduced pressure. To this residue was added benzene (100 ml), 4-chloro-6-isopropyl-2-(methylthio)pyrimidine (4.04 g), tetrakis(triphenylphosphine)palladium(0) (500 mg), and sodium carbonate (20 ml of 2M), was heated to reflux (about 80° to 90°C) for 14 hours. The mixture was filtered, and solvent was removed under reduced pressure. The residue was chromatographed on silica gel, eluting with 2% ethyl acetate/hexane, to give impure 4-(4-fluoronaphth-1-yl)-6-isopropyl-2-(methylthio)pyrimidine (4.87 g), which was used in the next reaction with no further purification.

B. Similarly, replacing 4-chloro-6-isopropyl-2-(methylthio)pyrimidine with other compounds of formula (16), and following the procedures of Preparation 5A above, the following compounds of formula (17) were prepared:

4-(4-fluoronaphth-1-yl)-6-methyl-2-(methylthio)-pyrimidine, m.p. 140-142°C; and

4-(4-fluoronaphth-1-yl)-6-methoxy-2-(methylthio)-pyrimidine, ^{1}HNMR 8.19 (2H,m), 7.65 (3H,m), 7.25 (1H,dd,*J*=8,10 Hz), 6.45 (1H,s), 3.98 (3H,s), 2.55 (3H,s).

C. Similarly, replacing 4-chloro-6-isopropyl-2-(methylthio)pyrimidine with other compounds of formula (16) and following the procedures of Preparation 6A above, other compounds of formula (17) are prepared.

D. <u>Alternative Preparation of (17) where R^1 is Aralkyl, from Compounds of Formula (17) where R^1 is Alkyl</u>

A solution of 4-(4-fluoronaphth-2-yl)-6-methyl-2-(methylthio)-pyrimidine (0.500 g, 1.76 mmol) in tetrahydrofuran (2 ml) was added dropwise to a solution of lithium diisopropylamide (1.2 eq) in tetrahydrofuran (10 ml) cooled to -70°C. After stirring for 30 minutes, benzyl bromide (0.251 ml, 2.11 mmol) was added to the solution in

one portion. The solution was warmed to room temperature and diuted with ethyl acetate (50 ml), poured into water (50 ml). The organic layer was separated, dried over magnesium sulfate and concentrated *in vacuo*, and the resultant oil purified by column chromatography to give 4-(4-fluoronaphth-1-yl)-2-methylthio-6-phenethylpyrimidine (0.342 g, 52%).

E. Similarly, replacing 4-(4-fluoronaphth-2-yl)-6-methyl-2-(methylthio)pyrimidine with other compounds of formula (16) where R^1 is alkyl and following the procedures of Preparation 6D above, the following compounds of formula (17) were prepared:

4-(4-fluoronaphth-1-yl)-6-(2-hydroxyphenethyl)-2-(methylthio)pyrimidine; and

4-(4-fluoronaphth-1-yl)-6-(3-hydroxypropyl)-2-(methylthio)pyrimidine.

F. Similarly, replacing 4-(4-fluoronaphth-2-yl)-6-methyl-2-(methylthio)pyrimidine with other compounds of formula (16) and following the procedures of Preparation 6C above, where R^1 is lower alkyl, other compounds of formula (17) are prepared.

PREPARATION 7

Preparation of Compounds of Formula (18)

A. Preparation of (18) where R^1 is Isopropyl, R^2 is Hydrogen, and R^3 is 4-Fluoro-1-naphthyl

4-(4-Fluoronaphth-1-yl)-2-methylthio-6-phenethyl-pyrimidine (0.342 g, 0.914 mmol) was dissolved in methylene chloride at room temperature. *meta*-Chloroperoxybenzoic acid (55-60%, 0.554 g, 1.83 mmol) was added in small portions. After 16 hours, the reaction mixxture was washed with saturated aqueous sodium bisulfite. The organic layer was washed with saturated aqueous sodium bicarbonate and water, dried over magnesium sulfate, and concentrated *in vacuo* to give 4-(4-fluoronaphth-1-yl)-2-methylsulfonyl-6-phenethylpyrimidine (0.402 g, 97%) as an oil, ^{1}HNMR 8.07 (1H,m), 7.85 (1H,m), 7.47 (2H,m), 7.32 (1H,s), 7.13 (7H,m), 3.29 (2H,m), 3.07 (2H,m).

B. Similarly, replacing 4-(4-fluoronaphth-1-yl)-2-methylthio-6-phenethylpyrimidine with other compounds of formula (17), and following the procedure of Preparation 7A above, the following compounds of formula (18) were prepared.

4-(4-fluoronaphth-1-yl)-6-(2-hydroxyphenethyl)-2-methylsulfonyl-pyrimidine, m.p. 88.1-90.0°C;

4-(4-fluoronaphth-1-yl)-6-(3-hydroxypropyl)-2-methylsulfonyl-pyrimidine, ^{1}HNMR 8.21 (2H,m), 7.69 (1H,dd,*J*=5.3,8.2 Hz), 7.68 (1H,s), 7.61 (2H,m), 7.24 (1H,dd,*J*=8,10 Hz), 3.76 (2H,t,*J*=7.5 Hz), 3.40 (3H,s), 3.09 (2H,t,*J*=7.5 Hz), 2.11 (2H,m);

4-(4-fluoronaphth-1-yl)-6-methoxy-2-methylsulfonyl-pyrimidine, ^{1}HNMR 8.20 (2H,m), 7.64 (3H,m), 7.25 (1H,dd,*J*=8,10 Hz), 7.15 (1H,s), 4.20 (3H,s), 3.39 (3H,s); and

4-(4-fluoronaphth-1-yl)-6-isopropyl-2-methylsulfonyl-pyrimidine, m.p. 96.1-97.1°C.

C. Similarly, replacing 4-(4-fluoronaphth-1-yl)-2-methylthio-6-phenethylpyrimidine with other compounds of formula (17), and following the procedure of Preparation 7A above, other compounds of formula (18) are prepared.

EXAMPLE 1

Preparation of a Compound of Formula I

A. Preparation of I where R^1 and R^2 are Methyl, R^3 is Naphth-1-yl, and R^4 and R^5 are Hydrogen

A stirred heterogeneous solution of 1-naphthyl boronic acid (0.382 g), 2-amino-4-chloro-5,6-dimethylpyrimidine (0.350 g), tetrakis(triphenylphosphine)palladium(0) (0.153 g), ethyl alcohol (8 ml), water (4 ml), 1,2-dimethoxyethane (8 ml) and sodium carbonate (0.85 g), was heated to reflux (about 80° to 90°C) for 14 hours. The solution was then cooled to room temperature, filtered and extracted with ethyl acetate. The solvent was removed under reduced pressure and the resultant yellow solid was recrystallized to give 2-amino-5,6-dimethyl-4-(naphth-1-yl)-pyrimidine (0.213 g), m.p. 213.5-215.1°C.

B. Similarly, optionally replacing 2-amino-4-chloro-5,6-dimethylpyrimidine with other compounds of formula (4), and optionally replacing 1-naphthyl boronic acid with other compounds of formula (5), and following the procedures of Example 1A above, the following compounds of formula I were prepared:

2-amino-6-cyclopentyl-4-(naphth-1-yl)-pyrimidine, m.p. 146.8-147.4°C;

2-amino-6-(but-2-yl)-4-(naphth-1-yl)-pyrimidine, m.p. 109.6-110.8°C;

2-amino-6-(2-methylpropyl)-4-(naphth-1-yl)-pyrimidine hydrobromide, m.p. 147.0-151.5°C;

THIS SHEET HAS BEEN REPLACED

2-amino-6-(tert-butyl)-4-(naphth-1-yl)-pyrimidine, m.p. 161.0-161.3°C;

2-amino-6-benzyl-4-(naphth-1-yl)-pyrimidine, m.p. 147.9-148.2°C;

2-amino-6-cyclobutyl-4-(naphth-1-yl)-pyrimidine, m.p. 147-148°C;

2-amino-6-cyclopropyl-4-(naphth-1-yl)-pyrimidine, m.p. 182.8-184.0°C;

2-amino-4-(naphth-1-yl)-6-n-propylpyrimidine, m.p. 119.5-120.5°C;

2-amino-6-isopropyl-4-(naphth-1-yl)-pyrimidine, m.p. 124-126°C;

2-amino-5-fluoro-6-methyl-4-(naphth-1-yl)-pyrimidine, m.p. 155-157°C;

2-amino-6-ethyl-4-(naphth-1-yl)-pyrimidine hydrochloride, m.p. 157-160°C;

2,6-diamino-4-(naphth-1-yl)-pyrimidine hydrochloride, m.p. >290°C;

2-amino-6-trifluoromethyl-4-(naphth-1-yl)-pyrimidine, m.p. 152-154°C;

2-amino-4-(naphth-1-yl)-6-phenylpyrimidine hydrochloride, m.p. 232-236°C;

2-amino-4-(3-fluorophenyl)-6-methylpyrimidine, m.p. 140.6-141.4°C;

2-amino-4-(5-chlorothiophen-2-yl)-6-methylpyrimidine, m.p. 186.1-187.3°C;

2-amino-4-(3-methoxyphenyl)-6-methylpyrimidine, m.p. 125.8-129.6°C;


2-amino-6-methyl-4-(3-nitrophenyl)-pyrimidine, m.p. 198.5-199.6°C;

2-amino-4-(3-chloro-4-fluorophenyl)-6-methylpyrimidine, m.p. 163.8-165.5°C;

2-amino-4-(3,5-dichlorophenyl)-6-methylpyrimidine, m.p. 187.0-187.9°C;

2-amino-6-methyl-4-(3-trifluoromethylphenyl)-pyrimidine, m.p. 122.0-122.8°C;

This Sheet Has Been Replaced



2-amino-6-methyl-4-(naphth-1-yl)-pyrimidine hydrochloride, m.p. 226°C;

2-amino-4-(4-fluoronaphth-1-yl)-6-(3,3,3-trifluoropropyl)-pyrimidine hydrochloride, m.p. 152-155°C;

2-amino-4-(5-fluoronaphth-1-yl)-6-isopropylpyrimidine, m.p. 86-88°C;

2-amino-4-(2-fluoronaphth-1-yl)-6-isopropylpyrimidine hydrochloride, m.p. 205-206°C;

2-amino-4-(2-fluoronaphth-1-yl)-6-methoxypyrimidine hydrochloride, m.p. 189-190°C;

2-amino-4-(4-fluoronaphth-1-yl)-6-methoxypyrimidine hydrochloride, m.p. >280°C;

2-amino-4-(4-fluoronaphth-1-yl)-6-(2,2,2-trifluoroethoxy)-pyrimidine hydrochloride, m.p. 206.1-208°C;

2-amino-6-*tert*-butyl-4-(2-fluoronaphth-1-yl)-pyrimidine hydrochloride, m.p. 230-233°C;

2-amino-4-(2-fluoronaphth-1-yl)-6-methylpyrimidine, m.p. 149-150°C;

2-amino-4-(2-methylnaphth-1-yl)-6-isopropylpyrimidine hydrochloride, m.p. 193-194°C;

2-amino-4-(6-methylacenaphthen-5-yl)-6-methyl-pyrimidine, m.p. 198-199°C;

2-amino-6-cyclopropyl-4-(1*H*-indol-4-yl)-pyrimidine hydrochloride, m.p. >280°C;

2-amino-6-*tert*-butyl-4-(1*H*-indol-4-yl)-pyrimidine, m.p. 171-173°C;

2-amino-4-(8-hydroxymethylnaphth-1-yl)-6-methyl-pyrimidine, m.p. 206-208°C;

2-amino-4-(1*H*-indol-7-yl)-6-isopropylpyrimidine, m.p. 143-145°C;

2-amino-4-(4-amino-5-chloro-2-methoxyphenyl)-6-isopropylpyrimidine hydrochloride, m.p. 187.1-190.6°C;

2-amino-6-cyclobutyl-4-(1*H*-indol-4-yl)-pyrimidine, m.p. 225-226°C;

2-amino-6-(3-methylbutyl)-4-(naphth-1-yl)-pyrimidine hydrochloride, m.p. 151.5-153°C; and

2-amino-4-(4-amino-5-chloro-2-methoxyphenyl)-6-methylpyrimidine, m.p. 183-184°C.

C. Similarly, optionally replacing 2-amino-4-chloro-5,6-dimethylpyrimidine with other compounds of formula (4), and optionally replacing 1-naphthyl boronic acid with other compounds of formula (5), and following the procedures of Example 1A above, other compounds of formula I are prepared.

EXAMPLE 2
Alternative Preparation of a Compound of Formula I

A. Preparation of I where R^1 is n-Propyl, R^2 is Hydrogen, R^3 is 4-Fluoronaphth-1-yl, and R^4 and R^5 are Hydrogen

To a stirred solution of 1-bromo-4-fluoronaphthalene (0.5 g) in 10 ml of tetrahydrofuran at -78°C under nitrogen was added n-butyllithium (1.6M, 1.53 ml) dropwise. The solution was allowed to stir for 5 minutes, then trimethoxyborane (0.33 ml) was added dropwise. The solution was allowed to warm to room temperature and the solvent removed under reduced pressure to give a solid, dimethoxy-(4-fluoronaphth-1-yl)borane, a compound of formula (7).

The solid was dissolved in 5 ml of benzene, and 2-amino-4-chloro-6-n-propylpyrimidine (0.381 g), tetrakis-(triphenylphosphine)palladium(0) (0.100 g) and 6 ml of 2M aqueous sodium carbonate were added. The heterogeneous solution was heated to reflux (about 80° to 90°C) for 1 hour, then the solution cooled to room temperature, diluted with ethyl acetate and filtered. The filtrate was concentrated *in vacuo* and the residue chromatographed on silica gel, eluting with a mixture of hexanes/ethyl acetate, to give 2-amino-4-(4-fluoronaphth-1-yl)-6-n-propylpyrimidine (0.110 g), m.p. 136.9-137.4°C.

B. Similarly, optionally replacing 1-bromo-4-fluoro-naphthalene with other compounds of formula (6), and optionally replacing 2-amino-4-chloro-6-n-propylpyrimidine with other compounds of formula (4), and following the procedures of Example 2A above, the following compounds of formula I were prepared:

2-amino-4-(4-chloronaphth-1-yl)-6-(2-methylpropyl)-pyrimidine hydrochloride, m.p. 198.2-199.8°C;

2-amino-4-(4-fluoronaphth-1-yl)-6-(2-methylpropyl)-pyrimidine hydrochloride, m.p. 191.3-193.0°C;

2-amino-4-(4-chloronaphth-1-yl)-6-ethylpyrimidine, m.p. 142.7-143.2°C;

2-amino-4-(4-methylnaphth-1-yl)-6-isopropylpyrimidine, m.p. 143.9-145.0°C;

2-amino-6-(tert-butyl)-4-(4-fluoronaphth-1-yl)-pyrimidine hydrochloride, m.p. 193-194°C;

2-amino-4-(4,5-dimethylnaphth-1-yl)-6-methylpyrimidine, m.p. 194-195°C;

2-amino-4-(4,5-difluoronaphth-1-yl)-6-isopropyl-pyrimidine, m.p. 123-124°C;

2-amino-4-(4-chloronaphth-1-yl)-6-isopropylpyrimidine hydrochloride, m.p. 183.2-185.6°C;

2-amino-6-cyclopropyl-4-(4-fluoronaphth-1-yl)-pyrimidine, m.p. 150.7-151.5°C;

2-amino-6-cyclopropylmethyl-4-(4-fluoronaphth-1-yl)-pyrimidine hydrochloride, m.p. 128.4-129.4°C;

2-amino-6-cyclobutyl-4-(4-fluoronaphth-1-yl)-pyrimidine hydrochloride, m.p. 168-171°C;

2-amino-4-(4,5-difluoronaphth-1-yl)-6-methylpyrimidine, m.p. 200°C;

2-amino-4-(1H,3H-benzo[de]isochromen-6-yl)-6-methylpyrimidine, m.p. 216-218°C;

2-amino-4-(acenaphth-5-yl)-6-isopropylpyrimidine, m.p. 167-168°C;

2-amino-6-methyl-4-(phenanthren-9-yl)-pyrimidine, m.p. 191.3-191.8°C;

2-amino-4-(4-methylnaphth-1-yl)-6-methylpyrimidine, m.p. 175.2-176.6°C;

2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine hydrochloride, m.p. 156-158°C;

2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine maleate, m.p. 155-157°C;

2-amino-6-ethyl-4-(2-methyl-4-fluoronaphth-1-yl)-pyrimidine, m.p. 121-122°C;

2-amino-4-(acenaphth-5-yl)-6-methylpyrimidine, m.p. 211-213°C;

2-amino-4-(isoquinolin-4-yl)-6-methylpyrimidine, m.p. 212.0-213.5°C;

2-amino-4-(quinolin-8-yl)-6-methylpyrimidine, m.p. 194.8-195.5°C;

2-amino-4-(4-fluoronaphth-1-yl)-pyrimidine, m.p. 203.4-204.1°C;

2-amino-6-ethyl-4-(4-fluoronaphth-1-yl)-pyrimidine hydrochloride, m.p. 198-199°C;

2-amino-4-(4-fluoronaphth-1-yl)-6-methylpyrimidine hydrochloride, m.p. 238.3-238.6°C; and

2-amino-4-(2-methylnaphth-1-yl)-6-methylpyrimidine hydrochloride, m.p. 216.6-219.4°C.

C. Similarly, optionally replacing 1-bromo-4-fluoronaphthalene with other compounds of formula (6), and optionally replacing 2-amino-4-chloro-6-n-propylpyrimidine with other compounds of formula (4), and following the procedures of Example 2A above, other compounds of formula I are prepared.

THIS SHEET HAS BEEN REPLACED

EXAMPLE 3

Alternative Preparation of a Compound of Formula I

A. Preparation of I where R^1 is Methyl, R^2 is Hydrogen, R^3 is 6-Methoxy-3,4-Dihydro-2H-Quinolin-1-yl, and R^4 and R^5 are Hydrogen

A flask containing 6-methoxy-1,2,3,4-tetrahydroquinoline (1.33 g), 2-amino-4-chloro-6-methylpyrimidine (1.00 g), sulfuric acid (0.6 g), and 100 ml of water was heated on a steam bath for 2 hours. The solution was then cooled to room temperature and treated with ammonium hydroxide until the solution was basic (pH 8-9). The resultant solid, which precipitated from solution, was collected by filtration and recrystallized from ethyl alcohol to give 2-amino-4-(6-methoxy-3,4,-dihydro-2H-quinolin-1-yl)-6-methylpyrimidine (0.93 g), m.p. 175.2-175.9°C.

B. Similarly, optionally replacing 6-methoxy-1,2,3,4-tetrahydroquinoline with other compounds of formula (8), and optionally replacing 2-amino-4-chloro-6-methylpyrimidine with other compounds of formula (4), and following the procedures of Example 3A above, the following compounds of formula I were prepared:

2-amino-4-(6-fluoro-3,4-dihydro-2H-quinolin-1-yl)-6-methylpyrimidine, m.p. 156-157°C;

2-amino-6-chloro-4-(3,4-dihydro-2H-quinolin-1-yl)-pyrimidine hydrochloride, m.p. >180°C (dec);

2-amino-4-(indol-1-yl)-6-methylpyrimidine hydrochloride, m.p. 256-260°C;

2,6-diamino-4-(3,4-dihydro-2H-quinolin-1-yl)-pyrimidine dihydrochloride, m.p. 196-197°C;

6-(3,4-dihydro-2H-quinolin-1-yl)-9H-purin-2-ylamine, m.p. 203.5-204.0°C;

2-amino-4-(2-methyl-3,4-dihydro-2H-quinolin-1-yl)-6-methylpyrimidine, m.p. 141-144°C;

This Sheet Has Been Replaced



THIS SHEET HAS BEEN REPLACED

2-amino-4-(6-methoxy-3,4-dihydro-2H-quinolin-1-yl)-6-trifluoromethylpyrimidine, m.p. 175.6-177.5°C;

2-amino-4-(3,4-dihydro-2H-quinolin-1-yl)-6-ethylpyrimidine, m.p. 141.4-142.1°C;

2-amino-6-methyl-4-(6-methyl-3,4-dihydro-2H-quinolin-1-yl)-pyrimidine, m.p. 170.6-171.4°C;

2-amino-4-(3,4-dihydro-2H-quinolin-1-yl)-6-trifluoromethylpyrimidine, m.p. 162-164°C;

2-amino-4-(6-fluoro-2-methyl-3,4-dihydro-2H-quinolin-1-yl)-6-methylpyrimidine, m.p. 154.9-155.6°C;

4-(3,4-dihydro-2H-quinolin-1-yl)-2-(methylamino)-pyrimidine ;

[2-(3,4-dihydro-2H-quinolin-1-yl)-pyrimidin-4-yl]methylamine;

2-amino-6-methyl-4-(2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-pyrimidine, m.p. 182.6-184.2°C;

2-amino-4-(7,8-dihydro-6H-5-oxa-9-benzocyclohepten-9-yl)-6-methylpyrimidine, m.p. 189.9-192.0°C;

2-amino-4-(2,3-dihydro-benzo[1,4]oxazin-4-yl)-6-methylpyrimidine, m.p. 177.7-178.5°C;

2-amino-4-(2,3-dihydro-indol-1-yl)-6-methylpyrimidine, m.p. 247.7-248.0°C;

2-amino-4-(2-methyl-2,3-dihydro-indol-1-yl)-6-methylpyrimidine, m.p. 182.9-183.4°C;

2-amino-4-(3,4-dihydro-2H-quinolin-1-yl)-6-methylpyrimidine hydrochloride, m.p. 261.5-262.3°C; and

2-amino-4-(3,4-dihydro-1H-isoquinolin-2-yl)-6-methylpyrimidine, m.p. 142.2-143.3°C.

C. Preparation of I where R^1 is Chloro, R^2 is Hydrogen, R^3 is 3,4-Dihydro-2H-Quinolin-1-yl, and R^4 and R^5 are Hydrogen

1,2,3,4,-tetrahydroquinoline (2.66 g, 20 mmol) and 2-amino-4,6-dichloropyrimidine (3.30 g, 20 mmol) were dissolved in 10 ml of N,N-dimethylformamide (DMF), and the entire solution was heated to 70-90°C for 24 hours. DMF was

This Sheet Has Been Replaced

removed under vacuum, and the residue was refluxed with ethyl acetate to give 4.0 g of a solid; the solid was chromatographed on silica gel, eluting with methylene chloride, to give 2-amino-6-chloro-4-(3,4-dihydro-2H-quinolin-1-yl)-pyrimidine (400 mg), m.p. 167.1-167.5°C; 2-amino-6-chloro-4-(3,4-dihydro-2H-quinolin-1-yl)-pyrimidine hydrochloride, m.p. 179°C (dec.).

D. Similarly, optionally replacing 6-methoxy-1,2,3,4-tetrahydroquinoline with other compounds of formula (8), and optionally replacing 2-amino-4-chloro-6-methylpyrimidine with other compounds of formula (4), and following the procedures of Example 3A or 3C above, other compounds of formula I are prepared.

EXAMPLE 4

Alternative Preparation of a Compound of Formula I

A. Preparation of I where R^1 is N,N-diethylamino, R^2 is Hydrogen, R^3 is 3,4-Dihydro-2H-Quinolin-1-yl, and R^4 and R^5 are Hydrogen

Excess diethylamine was added to a solution of 2-amino-6-chloro-4-(1,2,3,4-tetrahydroquinolin-1-yl)-pyrimidine (250 mg) in 5 ml of ethylene glycol. The mixture was heated for 2 days at 100°C. The crude product was purified by chromatography to give 300 mg of a solid. Treatment of the solid with hydrochloric acid-ethanol alcohol yielded 2-amino-6-diethylamino-4-(3,4-dihydro-2H-quinolin-1-yl)-pyrimidine hydrochloride, m.p. 167-170°C.

B. Similarly, optionally replacing diethylamine with other amines of formula HNR^6R^7, and optionally replacing 2-amino-6-chloro-4-(1,2,3,4-tetrahydroquinolin-1-yl)-pyrimidine with other compounds of formula I where R^1 is chloro, and

following the procedures of Example 4A above, other compounds of formula I where R^1 is $-NR^6R^7$ are prepared.

EXAMPLE 5

Alternative Preparation of a Compound of Formula I

A. Preparation of I where R^1 is Methyl, R^2 is Hydrogen, R^3 is 1H-Indol-4-yl, and R^4 and R^5 are Hydrogen

4-Acetylindole (0.101 g) was refluxed in 5 ml of ethyl acetate. Sodium hydride (0.20 g, 60% oil dispersion) was added in portions to the refluxing solution until thin layer chromatography analysis showed complete consumption of the starting material. The reaction mixture was quenched with water and acidified to pH 3. The ethyl acetate layer was dried (magnesium sulfate) and concentrated to give a crude product. The crude material was chromatographed on silica gel, eluting with a 4:1 mixture of hexane/ethyl acetate to give 1-(1H-indol-4-yl)-1,3-butanedione (0.104 g), a compound of formula (11), m.p. 104-105°C.

B. 1-(1H-Indol-4-yl)-1,3-butanedione (0.096 g) was mixed with guanidine carbonate (0.070 g), and the mixture was heated to 150°C for 3 hours. Additional guanidine carbonate (0.070 g) was added, and the mixture continued to heat for another 2 hours. The reaction mixture was warmed with ethyl acetate, filtered, and the ethyl acetate layer was concentrated to give a solid (0.090 g). Flash chromatography on silica gel and eluting with a 1:1 mixture of hexane/ethyl acetate, yielded 2-amino-4-(1H-indol-4-yl)-6-methylpyrimidine (0.029 g), m.p. 242 -243.5°C.

C. Similarly, replacing 4-acetylindole with 1-acetylnaphthalene in step 5A above, and replacing guanidine carbonate with l-arginine in step B, and following the procedures of Example 5A and 5B, the compound 2-amino-5-(6-

methyl-4-naphth-1-yl)-pyrimidin-2-ylamino)-pentanoic acid, m.p. 264-266°C was prepared.

D. Similarly, replacing 4-acetylindole with ethyl(1-naphthoyl)acetate in step 5A, and following the procedures of Example 5A and 5B, the compound 2-amino-6-methyl-4-(naphth-1-yl)-pyrimidine hydrochloride, m.p. 270-272°C was prepared.

E. Similarly, replacing 1-(1H-indol-4-yl)-1,3-butanedione with 1-(3-chlorophenyl)-1,3-butanedione and following the procedures of Example 5B above, the compound 2-amino-4-(3-chlorophenyl)-6-methylpyrimidine, m.p. 131.6-132.3°C was prepared.

F. Preparation of I where R^1 is Methyl, R^2 is Hydrogen, R^3 is 2,3-dihydro-1,4-benzodioxin-5-yl, and R^4 and R^5 are Hydrogen

1-(2,3-Dihydro-1,4-benzodioxin-5-yl)-ethanone (1.2 g) was dissolved in 20 ml of ethyl acetate, and sodium hydride (0.33 g, 60% oil dispersion) was added. The reaction mixture was heated to 80°C overnight, quenched with water, and neutralized with carbon dioxide to give an oily product of 1-(2,3-dihydro-1,4-benzodioxin-5-yl)butan-1,3-dione (0.37 g).

The 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-butan-1,3-dione (0.37 g), was mixed with guanidine carbonate (0.22 g), and the mixture was heated to 135°C for 1 hour. The dark product was taken up in methylene chloride, filtered, and concentrated. The residue was chromatographed on silica gel, eluting with a 3:2 mixture of ethyl acetate/hexane, to give a solid (0.16 g), which was treated with hydrochloric acid-ethanol to give 2-amino-4-(2,3-dihydro-1,4-benzodioxin-5-yl)-6-methylpyrimidine hydrochloride (0.125 g), m.p. 240-242°C.

This Sheet Has Been Replaced

G. Preparation of I where R^1 and R^2 are Hydrogen, R^3 is 1-methylindol-3-yl, and R^4 and R^5 are Hydrogen

3-Acetyl-1-methylindole (0.870 g) was dissolved in 3 ml of absolute ethanol. Tert-butoxybis(dimethylamino)methane (Bredereck's reagent) (0.960 g) in 3 ml of ethanol was added to this solution at reflux temperature. The solution was refluxed for 2 days and the solvent was removed at room temperature under vacuum. The residue was triturated with a 7:3 mixture of hexane/ethyl acetate to give a solid (0.094 g).

The solid was mixed with guanidine carbonate (0.037 g) and the mixture was heated to 120°C for 14 hours. The reaction mixture was dissolved in hot absolute ethyl alcohol, filtered, and recrystallized to give a white, crystalline solid of 2-amino-4-(1-methylindol-3-yl)-pyrimidine (0.039 g). Treatment of the crystalline solid with hydrochloric acid-ethyl alcohol and recrystallization of the salt from ethanol gave 2-amino-4-(1-methylindol-3-yl)-pyrimidine hydrochloride (0.0098 g), m.p. 274-276°C.

H. Preparation of I where R^1 is Isopropyl, R^2 is Hydrogen, R^3 is 4,7-difluoronaphth-1-yl, and R^4 and R^5 are Hydrogen

1-(4,7-difluoronaphth-1-yl)-ethanone (0.150 g, 0.72 mmol) was dissolved in dry dioxane (1 ml) and cooled to 0°C. Sodium hydride (0.145 g, 3.6 mmol, 60 wt.% dispersion) was added and the reaction mixture was stirred for 1 hour at room temperature. Ethyl isobutyrate (1.0 ml, 7.2 mmol) was added in one portion and the solution was heated to reflux for 15 minutes. After cooling to room temperature, the reaction mixture was poured onto 10% aqueous hydrochloric acid and extracted with methylene chloride. The organic layer was dried over sodium sulfate and purified by column

chromatography to give 1-(4,7-difluoronaphth-1-yl)-4-methylpentane-1,3-dione (0.120 g, 72%).

I. 1-(4,7-difluoronaphth-1-yl)-4-methylpentane-1,3-dione (0.114 g, 0.5 mmol) was combined with guanidine carbonate (0.180 g, 0.5 mmol) and heated to 150°C for 6 hours. The reaction was cooled to room temperature and directly purified by column chromatography to give 2-amino-4-(4,7-difluoronaphth-1-yl)-6-isopropylpyrimidine (0.052 g, 34%), m.p. 103-105°C.

J. Similarly, replacing 1-(4,7-difluoronaphth-1-yl)-ethanone with 1-(4,6-difluoronaphth-1-yl)-ethanone, 1-(4,8-difluoronaphth-1-yl)-ethanone, 1-(4-methoxynaphth-1-yl)-ethanone, or 1-(1-methyl-1*H*-indol-4-yl)-ethanone in step 5H, and optionally replacing ethyl isobutyrate with 4,4-dimethyl-3-oxopentanoate or 4,4-dimethyl-3-oxopentanoate, or ethyl-2-fluoroisobutyrate, and guanidine with substituted guanidine salts in step 5I, and following the procedures of Example 5H and 5I, the following compounds were prepared:

2-amino-4-(4,6-difluoronaphth-1-yl)-6-isopropyl-pyrimidine hydrochloride, m.p. 136-138°C;

2-amino-4-(4,8-difluoronaphth-1-yl)-6-isopropyl-pyrimidine hydrochloride, m.p. 216-219°C;

2-amino-4-(4-methoxynaphth-1-yl)-6-isopropylpyrimidine hydrochloride, m.p. 196-197°C;

2-amino-6-*tert*-butyl-4-(4-methoxynaphth-1-yl)-pyrimidine hydrochloride, m.p. 219-220.5°C;

2-amino-4-(1*H*-indol-4-yl)-6-isopropylpyrimidine hydrochloride, m.p. 211-212°C;

2-amino-4-(1-methyl-1*H*-indol-4-yl)-6-isopropyl-pyrimidine, m.p. 128-130°C;

2-amino-4-(4-fluoronaphth-1-yl)-6-(1-fluoro-1-methylethyl)-pyrimidine, m.p. 135.5-137.0°C;

2-amino-4-(4-fluoronaphth-1-yl)-6-(1-fluoro-1-methylethyl)-pyrimidine hydrochloride, m.p. 186.6-187.8°C;

4-(4-fluoronaphth-1-yl)-6-(1-fluoro-1-methylethyl)-2-methylaminopyrimidine, m.p. 149-151°C;

2-amino-4-(4-methoxynaphth-1-yl)-6-methylpyrimidine hydrochloride, m.p. 247.0-249.5°C;

2-amino-6-ethyl-4-(4-methoxynaphth-1-yl)-pyrimidine hydrochloride, m.p. 218.5-218.9°C; and

2-amino-4-(4,6-difluoronaphth-1-yl)-6-(1-fluoro-1-methylethyl)-pyrimidine hydrochloride, m.p. 129.6-131.3°C.

EXAMPLE 6

Alternative Preparation of a Compound of Formula I

A. Preparation of I where R^1 is Chloro, R^2 is Hydrogen, R^3 is Naphth-1-yl, and R^4 and R^5 are Hydrogen

2-Amino-6-hydroxy-4-(naphth-1-yl)-pyrimidine (900 mg) was added to a solution of chlorosulfonic acid (0.05 ml) in 2.5 ml of phosphorus oxychloride, and the mixture was stirred at 95°C for 6 hours. The mixture was poured onto ice, neutralized with potassium carbonate, and extracted with ethyl acetate. The crude product (70 mg) was purified by silica gel chromatography, eluting with methylene chloride, and treated with hydrochloric acid-ethanol to give 2-amino-6-chloro-4-(naphth-1-yl)-pyrimidine hydrochloride (25 mg), m.p. 248-250°C.

B. Preparation of I where R^1 and R^2 are Hydrogen, R^3 is Naphth-1-yl, and R^4 and R^5 are Hydrogen

2-Amino-6-chloro-4-(naphth-1-yl)-pyrimidine (170 mg) was dissolved in 10 ml of methyl alcohol at 0°C. 10% Palladium on activated carbon (70 mg) and approximately 1 ml of 20% sodium hydroxide were added to the solution, and the mixture was hydrogenated (1 atmosphere) for 1 hour to give solid 2-amino-4-(naphth-1-yl)-pyrimidine (80 mg). Treatment of the solid with hydrochloric acid-ethyl alcohol yielded

2-amino-4-(naphth-1-yl)-pyrimidine hydrochloride (25 mg), m.p. 181-184°C.

EXAMPLE 7

Alternative Preparation of a Compound of Formula I

A. Preparation of I where R^1 is Methoxy, R^2 is Hydrogen, R^3 is Naphth-1-yl, and R^4 and R^5 are Hydrogen

1-Acetonaphthalene (33 g) in carbon disulfide (15 g) was added over 15 minutes to a 12°C solution containing 195 ml of 1M potassium tert-butoxide in 400 ml of ether. The reaction mixture was allowed to warm to room temperature, re-cooled to 10-12°C, and then methyl iodide (55.0 g) was added dropwise over 45 minutes. The reaction mixture was brought to room temperature for 16 hours, filtered, and concentrated. The residue was recrystallized from 125 ml of methyl alcohol to give 3,3-(bis-methylsulfanyl)-(1-naphth-1-yl)-prop-2-en-1-one (20.1 g), m.p. 73-79°C.

B. The 3,3-(bis-methylsulfanyl)-(1-naphthalen-1-yl)prop-2-en-1-one (1.28 g) was added to 10 ml of a methanolic solution of sodium hydride (640 mg, 60% oil dispersion) and guanidine carbonate (630 g). The reaction mixture was refluxed for 6 hours, poured into ethyl acetate, and washed with saturated sodium bicarbonate, water, and brine. The organic layer was dried over potassium carbonate and concentrated to about 5 ml to give a crystalline solid of 2-amino-6-methoxy-4-(naphth-1-yl)-pyrimidine, m.p. 159.6-159.8°C. Treatment of the crystalline solid with hydrochloric acid-ethyl alcohol gave 2-amino-4-methoxy-6-(naphth-1-yl)-pyrimidine hydrochloride (300 mg), m.p. 184-185°C.

C. Similarly, replacing the methanolic solution with the corresponding alcohol (ethylene glycol, isopropyl alcohol,

ethyl alcohol) and following the procedures of Example 7B above, the following compounds of formula I were prepared:

2-amino-6-(2-hydroxyethoxy)-4-(naphth-1-yl)-pyrimidine hydrochloride, m.p. 199-201°C;

2-amino-6-isopropyloxy-4-(naphth-1-yl)-pyrimidine hydrochloride, m.p. 165-167°C; and

2-amino-6-ethoxy-4-(naphth-1-yl)-pyrimidine hydrochloride, m.p. 194-195°C.

D. Preparation of I where R^1 is Methylthio, R^2 is Hydrogen, R^3 is Naphth-1-yl, and R^4 and R^5 are Hydrogen

The 3,3-(bis-methylsulfanyl)-(1-naphth-1-yl)-prop-2-en-1-one (1.13 g) was added to a mixture of sodium hydride (0.38 g, 60% oil dispersion) and guanidine carbonate (0.40 g) in 10 ml of N,N-dimethylformamide (DMF) at room temperature. After 1 hour, the mixture was heated to 150°C for 5 hours. Extractive work-up gave a crude product which was chromatographed on silica gel, eluting with a 6:1 mixture of hexane/ethyl acetate to give 2-amino-4-methylthio-6-(1-naphthyl)-pyrimidine (140 mg). Treatment of the free base with hydrochloric acid-ethyl alcohol gave 2-amino-6-methylthio- 4-(naphth-1-yl)-pyrimidine hydrochloride (80 mg), m.p. 255-259°C (dec.).

EXAMPLE 8

Alternative Preparation of a Compound of Formula I

A. Preparation of I where R^1 is Isopropyl, R^2 is Hydrogen, R^3 is Naphth-1-yl, R^4 is Ethyl and R^5 is Hydrogen

4-(4-fluoronaphth-1-yl)-6-isopropyl-2-methylsulfonylpyrimidine (0.100 g, 0.29 mmol) was added to a solution of ethylamine (0.33 ml, 5.8 mmol) in ethanol (1 ml). The reaction vessel was placed in a sonication bath for 6 hours at a bath temperature of 45°C. The ethanol was removed *in vacuo* leaving a viscous oil. The oil was

crystallized from ethanol and water to give 2-ethylamino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine (49%), m.p. 77-78°C.

B. Similarly, replacing ethylamine with other amines of formula NHR^4R^5 and optionally replacing 4-(4-fluoronaphth-1-yl)-6-isopropyl-2-methylsulfonylpyrimidine with other compounds of formula (18), and following the procedures of Example 8A above, the following compounds of formula I were prepared:

4-(4-fluoronaphth-1-yl)-2-hydrazino-6-isopropyl-pyrimidine hydrochloride, m.p. 141-145°C;

4-(4-fluoronaphth-1-yl)-6-isopropyl-2-(piperazin-1-yl)-pyrimidine fumarate, m.p. 196.1-196.6°C;

2-(2-methoxyethylamino)-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine, m.p. 87.1-87.7°C;

4-(4-fluoronaphth-1-yl)-6-isopropyl-2-n-propylamino-pyrimidine, m.p. 99.6-99.9°C;

2-allylamino-4-(4-fluoronaphth-1-yl)-6-isopropyl-pyrimidine, m.p. 92.8-93.4°C;

4-(4-fluoronaphth-1-yl)-6-isopropyl-2-(piperidin-1-yl)-pyrimidine, m.p. 70-72°C;

2-benzylamino-4-(4-fluoronaphth-1-yl)-6-isopropyl-pyrimidine, m.p. 73-74°C;

2-cyclopropylamino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine, m.p. 100.1-100.8°C;

2-(2-hydroxyethylamino)-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine hydrochloride, m.p. 70-71°C;

4-(4-fluoronaphth-1-yl)-6-isopropyl-2-morpholino-pyrimidine, m.p. 81-83°C;

2-butylamino-4-(4-fluoronaphth-1-yl)-6-isopropyl-pyrimidine, m.p. 87-88°C;

2-butylamino-4-(4-fluoronaphth-1-yl)-6-methylpyrimidine hydrochloride, m.p. 137-139°C;

2-dimethylamino-4-(4-fluoronaphth-1-yl)-6-isopropyl-pyrimidine, m.p. 41-42°C;

THIS SHEET HAS BEEN REPLACED

4-(4-fluoronaphth-1-yl)-6-isopropyl-2-methylamino-pyrimidine, m.p. 115-116°C;

4-(4-fluoronaphth-1-yl)-6-(2-hydroxy-2-phenethyl)-2-methylaminopyrimidine, m.p. 138.1-139.2°C;

4-(4-fluoronaphth-1-yl)-6-phenethyl-2-methylamino-pyrimidine hydrochloride, m.p. 130.7-131.2°C;

4-(4-fluoronaphth-1-yl)-2-isopropylamino-6-methoxypyrimidine hydrochloride, m.p. 191.3-191.6°C;

2-(dimethylamino)ethylamino-4-(4-fluoronaphth-1-yl)-6-isopropypyrimidine hydrochloride, m.p. 176.5°C;

4-(4-fluoronaphth-1-yl)-6-isopropy-2-(methylamino)-ethylamino-pyrimidine hydrochloride, m.p. 152-153°C;

4-(4-fluoronaphth-1-yl)-6-(2-hydroxypropyl)-2-(methylamino)-ethylamino-pyrimidine hydrochloride, m.p. 125-130°C;

2-(2-hydroxyethyl)amino-4-(4-fluoronaphth-1-yl)-6-methoxypyrimidine hydrochloride, m.p. 191.3-191.6°C;

6-*tert*-butyl-4-(4-fluoronaphth-1-yl)-2-methylamino-pyrimidine, m.p. 129.4-130.0°C;

2-benzylamino-6-*tert*-butyl-4-(4-fluoronaphth-1-yl)-pyrimidine, m.p. 106.2-106.9°C;

6-*tert*-butyl-4-(4-fluoronaphth-1-yl)-2-isopropylamino-pyrimidine hydrobromide, m.p. 196.5-197.2°C;

6-*tert*-butyl-4-(4-fluoronaphth-1-yl)-2-(2-methoxy-ethyl)amino-pyrimidine hydrochloride, m.p. 114.5-117.8°C;

4-(4-fluoronaphth-1-yl)-6-isopropyl-2-(pyridin-4-yl)methylamino-pyrimidine, m.p. 149.1-149.5°C;


2-(2-amino)ethylamino-4-(4-fluoronaphth-1-yl)-6-isopropyl-pyrimidine fumarate, m.p. 172.4-172.6°C;

4-(4-fluoronaphth-1-yl)-6-isopropyl-2-(4-methoxy-phenyl)methylamino-pyrimidine hydrochloride, m.p. 65-67°C;

4-(4-fluoronaphth-1-yl)-2-(tetrahydro-2-furyl)methyl-amino-6-isopropyl-pyrimidine sodium, m.p. 72.7-73.8°C;

4-(4-fluoronaphth-1-yl)-2-(2-hydroxy)ethylamino-6-isopropyl-pyrimidine maleate, m.p. 101.9-104.1°C;

This Sheet Has Been Replaced



THIS SHEET HAS BEEN REPLACED

4-(4-fluoronaphth-1-yl)-2-(2-hydroxyethoxy)ethylamino-6-isopropyl-pyrimidine hydrobromide, m.p. 115.3-116.7°C;

2-(1,3-dihydroxyprop-2-yl)amino-4-(4-fluoronaphth-1-yl)-6-isopropyl-pyrimidine maleate, m.p. 125.3-126.6°C;

2-amino-4-(4-fluoronaphth-1-yl)-6-(2-methoxy)ethyl-pyrimidine maleate, m.p. 94-100°C;

2-amino-4-(4-fluoronaphth-1-yl)-6-phenethylpyrimidine maleate, m.p. 145-146°C; and

4-(4-fluoronaphth-1-yl)-2-(2-hydroxy)ethylamino-6-isopropylpyrimidine bromide.

C. Similarly, optionally replacing ethylamine with other amines of formula NHR^4R^5 and optionally replacing 4-(4-fluoronaphth-1-yl)-6-isopropyl-2-methylsulfonylpyrimidine with other compounds of formula (18), and following the procedures of Example 8A above, other compounds of formula I are prepared.

D. Alternative Preparation of I where R^1 is Isopropyl, R^2 is Hydrogen, R^3 is Naphth-1-yl, R^4 is Phenyl and R^5 is Hydrogen

Compounds of formula I are alternatively prepared by the treatment of 4-fluoronaphth-1-yl)-6-isopropyl-2-methylsulfonylpyrimidine with aniline in the absence of solvent at a higher temperatures of 120°C to afford 4-fluoronaphth-1-yl)-6-isopropyl-2-phenylaminopyrimidine, m.p. 85.7-86.3°C.

EXAMPLE 9

Preparation of an N-oxide of a Compound of Formula I

A. Preparation of The N-Oxide of a Compound of Formula I where R^1 is Methyl, R^2 is Hydrogen, R^3 is Naphth-1-yl, and R^4 and R^5 are Hydrogen

2-Amino-6-methyl-4-(naphth-1-yl)-pyrimidine (0.28 g) was dissolved in 15 ml of chloroform at 0°C. m-Chloroper-

This Sheet Has Been Replaced

THIS SHEET HAS BEEN REPLACED

benzoic acid (0.54 g) was added to the solution in portions over 5 minutes. After complete addition, the solution was warmed to 40°C for 30 minutes. The solution was washed with 10% aqueous sodium thiosulfate, 1M sodium hydroxide, and water. The chloroform layer was dried (sodium sulfate) and concentrated; the solid residue was recrystallized from ethyl alcohol-diethyl ether to give 2-amino-6-methyl-4-(naphth-1-yl)-pyrimidine-1-N-oxide (0.07 g), m.p. 228.7-229.5°C.

B. Similarly, replacing 2-amino-6-methyl-6-(naphth-1-yl)-pyrimidine with other compounds of formula I, and following the procedures of Example 9A above, the following N-oxides of compounds of formula I were prepared:

2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-3-N-oxide, m.p. 188-189°C;

2-amino-6-tert-butyl-4-(4-fluoronaphth-1-yl)-pyrimidine-3-N-oxide, m.p. 188.6-190.9°C;

2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-1-N-oxide hydrochloride, m.p. 207-208°C;

2,6-diamino-4-(naphth-1-yl)-pyrimidine-1-N-oxide, m.p. 254.1-255.5°C;

2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-1-N-oxide, m.p. 153-155°C;

2-acetylamino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-1-N-oxide, ^{1}HNMR (200 MHz), *J* 1.39 (d,6h), 2.51(s,3H), 3.81(m,1H), 7.21-7.27(m,2H), 7.62-7.68(m,3H), 8.10-8.23(m,1H), 8.38-8.41(m,1H);

2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-3-N-oxide, m.p. 188-189°C; and

4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-2-methylamino-1-N-oxide, m.p. 181-182.5°C.

C. Similarly, replacing 2-amino-6-methyl-4-(naphth-1-yl)-pyrimidine with other compounds of formula I and following

This Sheet Has Been Replaced

the procedures of Example 9A above, other N-oxides of compounds of formula I are prepared.

EXAMPLE 10

Preparation of a Compound of Formula I where R^1 is Hydroxyalkyl or Alkenyl

A. Preparation of I where R^1 is 1-Hydroxy-1-methylethyl or Isopropenyl, R^2 is Hydrogen, R^3 is Naphth-1-yl, and R^4 and R^5 are Hydrogen

Trifluoroacetic anhydride (0.211 ml, 1.50 mmol) was added to a solution of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-3-N-oxide (0.148 g, 0.498 mmol) in methylene chloride (5 ml) at room temperature. The mixture was stirred for 48 hours at room temperature and then poured into 1N aqueous sodium hydroxide. The organic layer was removed, concentrated *in vacuo*, purified by preparative thin layer chromatography to give a mixture of 2-amino-4-(4-fluoronaphth-1-yl)-6-(1-hydroxy-1-methylethyl)-pyrimidine (0.043 g, 29%), m.p. 181-184°C; and 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropenylpyrimidine (0.051 g, 36%), m.p. 138-140°C.

B. Similarly, replacing 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-3-N-oxide with other N-oxides of compounds of formula I and following the procedures of Example 10A above, other compounds of formula I where R^1 is hydroxyalkyl or alkenyl are prepared.

THIS SHEET HAS BEEN REPLACED

EXAMPLE 11

Preparation of a Compound of Formula I from Other Compounds of Formula I

A. Preparation of a Compound of Formula I where R^4 is acetyl, and R^5 is Hydrogen

2-Amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine (0.5 g) was dissolved in acetic anhydride (10 ml) and 4-dimethylaminopyridine (0.125 g) was added. The reaction mixture was stirred overnight at room temperature, then heated at 75° to 80°C for a total of 4 hours, and evaporated to dryness under vacuum. The residue was partitioned between water and ethyl acetate and then dried over magnesium sulfate. The diacetyl compound was isolated as an oil by evaporation and then dissolved in methanol (20 ml). The solution was treated with saturated sodium bicarbonate solution (2 ml) and allowed to stir overnight. The resulting monoacetyl derivative was isolated by evaporation to dryness and thorough drying under vacuum. The residue was taken up in boiling hexane and decanted from a small amount of insoluble residue and crystallized to yield 2-acetylamino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine, m.p. 115.4-116.7°C.

B. Preparation of a Compound of Formula I where R^4 and R^5 are Methanesulfonyl

2-Amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine (0.374 g) was dissolved in dichloromethane (25 ml) and cooled to 0°C. Triethyl amine (0.5 ml) was added to the solution and methanesulfonyl chloride (0.12 ml) in dichloromethane (5 ml) was added dropwise. After stirring the mixture for 15 miutes, another portion of triethyl amine (0.25 ml) and methanesulfonyl chloride (0.12 ml) were added sequentially. After 15 minutes, the process was repeated and tlc examination showed a single new product. The reaction mixture was evaporated to dryness and purified by

This Sheet Has Been Replaced



THIS SHEET HAS BEEN REPLACED

silica gel chromatography, eluting with 1:9 ethyl acetate:hexane mixture. The colorless crystalline material was recrystallized from hexane-ether to afford 2-(bis-methanesulfonyl)amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine, (354 mg, m.p. 143.8-144.2°C).

C. Preparation of a Compound of Formula I where R^4 is Methanesulfonyl and R^5 is Hydrogen

The 2-(bismethanesulfonyl)amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine product from Example 10B above (0.204 g) was dissolved in methanol (5 ml) and treated at room temperature with 2.5N sodium hydroxide solution (0.2 ml). The reaction mixture was stirred at room temperature for 1 hour. The mixture was partitioned between 1N hydrochloric acid and ethyl acetate. The organic layer was dried over magnesium sulfate and evaporated to dryness and recrystallized from hexane-ether to afford 2-(methanesulfonyl)amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine as a crystalline material, m.p. 276-276.9°C (prior decomposition at 273°C.

D. Preparation of a Compound of Formula I where R^4 is Phenylaminocarbonyl, and R^5 is Hydrogen

2-Amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine (288.3 mg) was dissolved in benzene (50 ml) and phenylisocyanate (119.1 mg) was added. The reaction mixture was heated to reflux for 48 hours, and the solvent was removed under vacuum. The residue was chromatographed on silica gel, eluting with 80:20 hexane:ethyl acetate, to yield 4-(4-fluoronaphth-1-yl)-6-isopropyl-2-phenylureido-pyrimidine (49.1 mg, m.p. 117-178).

This Sheet Has Been Replaced

THIS SHEET HAS BEEN REPLACED

EXAMPLE 11

This example illustrates the preparation of a representative pharmaceutical formulation for oral administration containing an active compound of formula I, *e.g.*, 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine.

Ingredients	Quantity per tablet, mgs.
Active Compound	200
Lactose, spray-dried	148
Magnesium stearate	2

The above ingredients are mixed and introduced into a hard-shell gelatin capsule.


Other compounds of formula I, such as those prepared in accordance with Examples 1-10, can be used as the active compound in the preparation of the orally administrable formulations of this example.

EXAMPLE 12

This example illustrates the preparation of another representative pharmaceutical formulation for oral administration containing an active compound of formula I, *e.g.*, 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine.

Ingredients	Quantity per tablet, mgs.
Active Compound	400
Cornstarch	50
Lactose	145
Magnesium stearate	5

This Sheet Has Been Replaced



THIS SHEET HAS BEEN REPLACED

The above ingredients are mixed intimately and pressed into single scored tablets.

Other compounds of formula I, such as those prepared in accordance with Examples 1-10, can be used as the active compound in the preparation of the orally administrable formulations of this example.

EXAMPLE 13

This example illustrates the preparation of a representative pharmaceutical formulation containing an active compound of formula I, *e.g.*, 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine.

An oral suspension is prepared having the following composition.

Ingredients	
Active Compound	1.0 g
Fumaric acid	0.5 g
Sodium chloride	2.0 g
Methyl paraben	0.1 g
Granulated sugar	25.5 g
Sorbitol (70% solution)	12.85 g
Veegum K (Vanderbilt Co.)	1.0 g
Flavoring	0.035 ml
Colorings	0.5 mg
Distilled water	q.s. to 100 ml

Other compounds of formula I, such as those prepared in accordance with Examples 1-10, can be used as the active compound in the preparation of the orally administrable formulations of this example.

This Sheet Has Been Replaced

THIS SHEET HAS BEEN REPLACED

EXAMPLE 14

This example illustrates the preparation of a representative pharmaceutical formulation for oral administration containing an active compound of formula I, *e.g.*, 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine.

An injectable preparation buffered to a pH of 4 is prepared having the following composition:

Ingredients	
Active Compound	0.2 g
Sodium Acetate Buffer Solution (0.4 M)	2.0 ml
HCl (1N)	q.s. to pH 4
Water (distilled, sterile)	q.s. to 20 ml

Other compounds of formula I, such as those prepared in accordance with Examples 1-10, can be used as the active compound in the preparation of the injectable formulations of this example.

EXAMPLE 15

This example illustrates the preparation of a representative pharmaceutical formulation for topical application containing an active compound of formula I, *e.g.*, 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine.

Ingredients	grams
Active compound	0.2-10
Span 60	2
Tween 60	2
Mineral oil	5
Petrolatum	10
Methyl paraben	0.15

This Sheet Has Been Replaced

THIS SHEET HAS BEEN REPLACED

Propyl paraben	0.05
BHA (butylated hydroxy anisole)	0.01
Water	q.s. to 100

All of the above ingredients, except water, are combined and heated to 60°C with stirring. A sufficient quantity of water at 60°C is then added with vigorous stirring to emulsify the ingredients, and water then added q.s. 100 g.

Other compounds of formula I, such as those prepared in accordance with Examples 1-10, can be used as the active compound in the preparation of the topical formulations of this example.

EXAMPLE 16

This example illustrates the preparation of a representative pharmaceutical formulation containing an active compound of formula I, *e.g.*, 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine.

A suppository totalling 2.5 grams is prepared having the following composition:

Ingredients	
Active Compound	500 mg
Witepsol H-15*	balance

(* triglycerides of saturated vegetable fatty acid; a product of Riches-Nelson, Inc., New York, N.Y.)

Other compounds of formula I, such as those prepared in accordance with Examples 1-10, can be used as the active compound in the preparation of the suppository formulations of this example.

This Sheet Has Been Replaced

THIS SHEET HAS BEEN REPLACED

EXAMPLE 17


Cloned Rat 5-HT2B Receptor Binding Assay

The following describes an *in vitro* binding assay utilizing cloned 5-HT_{2B} receptors radiolabelled with [^{3}H]-5HT.

Mouse NIH3T3 fibroblasts expressing cloned 5-HT_{2B} receptor were maintained in Dulbecco's Modified Eagle medium with 10% Fetal Calf Serum and 250 µg/ml G418 in 95/5% O_2/CO_2. The cells were harvested using 2 mM EDTA in phosphate buffered saline (calcium/magnesium free) and centrifuged (500 g). The cell pellet was homogenized using a Polytron P10 disrupter (setting 5, 5 sec) in homogenization buffer (Tris, 50 mM; Na_2EDTA, 5 mM) and the homogenate was centrifuged at 19,500 rpm using a Sorvall/Dupont RC5C centrifuge with an SS34 rotor (30,000-48,000 g, 15 minutes). The pellet was homogenized (setting 5, 5 sec) in homogenization buffer and the homogenate was centrifuged (30,000-48,000 g, 15 minutes). The pellet was homogenized (setting 5, 5 sec) in resuspension buffer (Tris, 50 mM; EDTA 0.5 mM) and the homogenate was centrifuged (30,000-48,000 g, 15 minutes). The pellet was homogenized (setting 5, 5 sec) in a small volume of resuspension buffer to give approximately $1.5x10^8$ cells/ml. The membranes were separated into 1 ml aliquots and stored at -70°C.

The membranes were thawed at room temperature and diluted with assay buffer calcium chloride$\xi 2H_2O$, 4.5 mM; Tris, 50 mM; 0.1% ascorbic acid). Specific binding is at least 90% of total binding with $1.5x10^6$ cells per assay tube. The membranes were homogenized (setting 5, 5 sec) and then the homogenate was added to assay tubes containing [^{3}H]-5HT ($2x10^{-10}$M) test compound ($1x10^{-10}$-$1x10^{-4}$M) and assay buffer (q.s. to 500 µλ). The assay mixture was

This Sheet Has Been Replaced



THIS SHEET HAS BEEN REPLACED

incubated at 40°C for 2 hours and then filtered over 0.1% polyethyleneimine pre-treated glass fiber filtermats using a Brandel cell harvester. The assay tubes were rinsed with cold assay buffer and dried by drawing air over the filter for 10 seconds. Radioactivity retained on the filters was determined by liquid scintillation counting. For each compound tested the concentration producing 50% inhibition of binding (IC_{50}) was determined using iterative curve fitting techniques.

Proceeding as in Example 17, compounds of the invention were found to have affinity for the 5-HT_{2B} receptor.

EXAMPLE 18

5-HT_{2A} 5-HT_{2B} 5-HT_{2C} Receptor Binding Methods

The following describes receptor binding methods in which ligands with high affinity for 5-HT_{2B} receptors were counter screened at 5-HT_{2A} and 5-HT_{2C} receptors to demonstrate selectivity.

5-HT_{2A} receptors were labelled with [^{3}H]ketanserin in human cortex, in Cos-7 cells expressing a cloned human 5-HT_{2A} receptor and in NIH-3T3 cells expressing the rat 5-HT_{2A} receptor. For competition binding studies the ligand concentration was approximately 0.1 nM. For saturation binding studies concentrations of radioligand ranged from 0.01 nM to 2.0 nM. Assays were conducted in 0.5 ml of assay buffer containing 50 mM Tris-HCl, 4 mM calcium chloride, and 0.1% ascorbic acid (pH 7.4 at 4°C). Non-specifc binding was defined with 10 mM unlabelled ketanserin. After a 60 minute incubation at 32°C, membranes were harvested onto filters treated with 0.1% polyethylenimine and the bound radioactivity was determined.

This Sheet Has Been Replaced

THIS SHEET HAS BEEN REPLACED

Human 5-HT_{2B} receptors were labelled in Cos-7 cells as described above except that the radioligand was [^{3}H]5-HT and that the assay buffer contained 10 mM pargyline and 0.1% ascorbic acid. For competition binding studies the radioligand concentration was approximately 0.4 nM while for saturation binding studies the concentration of [^{3}H]5-HT ranged from 0.05 to 8 nM. Non-specific binding was defined with 10 mM 5-HT. Incubations were for 120 minutes at 4°C.

5-HT_{2C} receptors were labelled in choroid plexus, Cos-7 cells expressing the human 5-HT_{2C} receptor and in NIH-3T3 expressing the rat 5-HT_{2C} receptor. Assays were conducted as described for the 5-HT_{2A} receptor except that the radioligand was [^{3}H]mesulergine. The radioligand concentration for competition studies was approximately 0.2 nM while for saturation binding studies the concentration ranged from 0.1 to 18 nM. Non-specific binding was defined with 10 µM unlabelled mesulergine.

Competition radioligand binding data was analyzed using a four parameter logistic equation and iterative curve-fitting techniques to obtain estimates of the IC_{50} and Hill slope. Kd values, determined from saturation binding studies were then used to calculate inhibition dissociation constants (Ki).

Proceeding as in Example 18, compounds of the invention were found to have affinity for the 5-HT_{2B} receptor.

EXAMPLE 19

5-HT_{2B} Receptor Tissue Based Functional Assay

The following describes an *in vitro* functional assay characterizing 5-HT receptors (the putative 5-HT_{2B}) in rat stomach fundus longitudinal muscle.

This Sheet Has Been Replaced



THIS SHEET HAS BEEN REPLACED

The rat stomach fundus was set up as described by Baxter *et al.*, (1994), *Brit. J. Pharmacol.*, **112**, 323-331. Strips of longitudinal muscle were obtained from the stomach fundus of male Sprague Dawley rats. The mucosa was removed and the strips were suspended with a resting tension of 1 gram in oxygenated Tyrode solution. The temperature was maintained at 37°C, and the experiments were conducted in the presence of pargyline (100 μM).

To test for antagonist actions concentration-response curves to 5-HT were generated in the presence or absence of the putative antagonist. Shild plots were generated to determine the affinity of the antagonist. To test for agonist the actions of the test compound alone, on the isolated tissue strip were quantified.

The compounds of the present invention were found to be antagonists at the 5-HT_{2B} receptor when tested by this method.

EXAMPLE 20

Anxiolytic Behavior Assay

The following describes an *in vivo* method for determining anxiolytic activity by measuring the extent the drug affects the natural anxiety of mice when exposed to a novel, brightly lighted environment.

Naive male C5BI/6J mice, 18-20 g, are kept in groups of 10 mice in quarters controlled for sound, temperature and humidity. Food and water are available ad libitum. The mice are kept on a 12 hour light and 12 hour dark cycle, with lights on at 6:00 a.m. and off at 6:00 p.m. All experiments begin at least 7 days after arrival on site.

This Sheet Has Been Replaced

The automated apparatus for detecting changes in exploration is obtained from Omni-Tech Electronics Columbus Ohio and is similar to that of Crawley and Goodwin (1980), as described in Kilfoil et al., cited previously. Briefly, the chamber consists of a plexiglass box (44 x 21 x 21 cm), divided into two chambers by a black plexiglass partition. The partition dividing the two chambers contains a 13 x 5 cm opening through which the mouse can easily pass. The dark chamber has clear sides and a white floor. A fluorescent tube light (40 watt) placed above the chambers provides the only illumination. The Digiscan Animal Activity Monitor System RXYZCM16 (Omni-Tech Electronics) records the exploratory activity of the mice within the test chambers.

Prior to commencement of the study the mice are given 60 min to acclimatize to the laboratory environment. After a mouse receives an intraperitoneal (i.p.) injection of either test compound or vehicle it is returned to its home cage for a 15 min post-treatment period. The mouse is then placed in the center of the light chamber and monitored for 10 minutes.

Anxiolysis is seen as a general increase in exploratory activity in the lighted area. An increase in exploratory activity is reflected by increased latency (the time for the mouse to move to the dark chamber when first placed in the center of the lighted area), increase in shuttle activity, increased or unaltered locomotor activity (number of grid lines crossed) and decreased time spent in the dark compartment.

The compounds of the present invention ameliorate anxiolytic behavior when tested by this method.

THIS SHEET HAS BEEN REPLACED

EXAMPLE 21

Withdrawal Anxiety Assay

The following describes an *in vivo* procedure for determining amelioration of the symptoms caused by withdrawal from addictive substances by measuring the extent the drug affects the anxiety that occurs in mice after chronically treating with an addictive substance and then abruptly ceasing the treatments.

Naive male BKW mice (25-30 g) are caged in groups of ten in quarters controlled for sound, temperature and humidity. Food and water are available ad libitum. The mice are kept on a 12 hour light cycle and 12 hour dark cycle, with lights on at 6:00 a.m. and off at 6:00 p.m. All experiments begin at least 7 days after arrival on site.

Levels of anxiety are determined by the two-compartment exploratory model of Crawley and Goodwin (see Example 14). Anxiolysis is seen as a general increase in exploratory activity in the lighted area. An increase in exploratory activity is reflected by increased latency (the time for the mouse to move to the dark chamber when first placed in the center of the lighted area), increased or unaltered locomotor activity (number of grid lines crossed), increased number of rears and decreased time spent in the dark compartment.

Increased exploratory activity in the lighted area is induced by treating the mice for 14 days with ethanol (8.0 % w/v in drinking water), nicotine (0.1 mg/kg, i.p., twice daily) or cocaine (1.0 mg/kg, i.p., twice daily). Anxiolysis is assessed 1, 3, 7 and 14 days after commencement of the drug regime. The treatment is abruptly ceased and exploratory activity in the lighted area is determined 8, 24 and 48 hours thereafter. Vehicle or test

This Sheet Has Been Replaced



compounds are administered during the withdrawal phase by intraperitoneal injection. Responses are represented as inhibition of the decrease in anxiolytic behavior after the ethanol, cocaine or nicotine treatment is ceased.


5

The compounds of the present invention show amelioration of the symptoms caused by withdrawal from addictive substances when tested by this method.

THIS SHEET HAS BEEN REPLACED

Claims

1. A compound of the formula:



I

wherein:

R^1 is hydrogen, alkyl, hydroxyalkyl, cycloalkyl, cycloalkyl lower alkyl, alkenyl, lower thioalkoxy, halo, fluoroalkyl, optionally substituted phenyl, optionally substituted phenyl lower alkyl, $-NR^6R^7$, $-CO_2R^8$, or $-O(CH_2)_nR^9$, in which

n is 1, 2, or 3;

R^6 and R^7 are hydrogen or lower alkyl;

R^8 is hydrogen or lower alkyl; and

R^9 is hydrogen, lower alkyl, hydroxy, hydroxy lower alkyl, lower alkenyl, or lower alkoxy;

R^2 is hydrogen, lower alkyl, lower alkoxy, halo, or lower fluoroalkyl;

R^3 is optionally substituted aryl;

R^4 is hydrogen, lower alkyl, optionally substituted phenyl-lower alkyl, hydroxy lower alkyl, acyl, $-(CH_2)_mNR^6R^7$, or $-SO_2R^{10}$; in which

m is an integer of 1-6;

R^6 and R^7 are hydrogen or lower alkyl, and

R^{10} is lower alkyl; and

R^5 is hydrogen or lower alkyl;

provided that:

when R^3 is naphthyl, pyridyl, thienyl, indol-1-yl, 2,3-dihydroindol-1-yl, or furanyl, and R^2, R^4 and R^5 are all hydrogen, R^1 is not methyl;

This Sheet Has Been Replaced

THIS SHEET HAS BEEN REPLACED

when R^3 is phenyl or naphthyl, R^1 is not $-NR^6R^7$;
when R^3 is naphthyl, R^1 is not phenyl; and
when R^3 is 1,2,3,4-tetrahydroquinolinyl, R^4 and R^5 are hydrogen;

or a pharmaceutically acceptable salt or N-oxide thereof.

2. The compound of Claim 1, wherein R^4 and R^5 are hydrogen or lower alkyl.

3. The compound of Claim 2, wherein R^1 is lower alkyl, fluoroalkyl, or hydroxyalkyl, and R^3 is optionally substituted 1-naphthyl, or a pharmaceutically acceptable salt or N-oxide thereof.

4. The compound of Claim 3, wherein R^1 is methyl, R^2, R^4, and R^5 are hydrogen, and R^3 is 2-methylnaphth-1-yl, namely 2-amino-4-(2-methylnaphth-1-yl)-6-methylpyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

5. The compound of Claim 3, wherein R^1 is isopropyl, R^2, R^4, and R^5 are hydrogen, and R^3 is 4-fluoronaphth-1-yl, namely 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

6. The compound of Claim 5, wherein the N-oxide is at the 1-position, namely 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-1-N-oxide.

7. The compound of Claim 3, wherein R^1 is 1-fluoro-1-methylethyl, R^2, R^4, and R^5 are hydrogen, and R^3 is 4-fluoronaphth-1-yl, namely 2-amino-4-(4-fluoronaphth-1-yl)-6-(1-fluoro-1-methylethyl)-pyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

This Sheet Has Been Replaced

THIS SHEET HAS BEEN REPLACED

8. The compound of Claim 3, wherein R^1 is 1-hydroxy-1-methylethyl, R^2, R^4, and R^5 are hydrogen, and R^3 is 4-fluoronaphth-1-yl, namely 2-amino-4-(4-fluoronaphth-1-yl)-6-(1-hydroxy-1-methylethyl)-pyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

9. The compound of Claim 3, wherein R^1 is 1-fluoro-1-methylethyl, R^2, R^4, and R^5 are hydrogen, and R^3 is 4,6-difluoronaphth-1-yl, namely 2-amino-4-(4,6-difluoronaphth-1-yl)-6-(1-fluoro-1-methylethyl)-pyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

10. The compound of Claim 3, wherein R^1 is isopropyl, R^2 and R^4 are hydrogen, R^5 is methyl, and R^3 is 4-fluoronaphth-1-yl, namely 2-methylamino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

11. The compound of Claim 3, wherein R^1 is 2-methylpropyl, R^2, R^4, and R^5 are hydrogen, and R^3 is 4-fluoronaphth-1-yl, namely 2-amino-4-(4-fluoronaphth-1-yl)-6-(2-methylpropyl)-pyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

12. The compound of Claim 3, wherein R^1 is tert-butyl, R^2, R^4, and R^5 are hydrogen, and R^3 is 4-fluoronaphth-1-yl, namely 2-amino-6-(tert-butyl)-4-(4-fluoronaphth-1-yl)-pyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

13. The compound of Claim 2, wherein R^1 is lower alkyl and R^3 is optionally substituted indole, or a pharmaceutically acceptable salt or N-oxide thereof.

14. The compound of Claim 13, wherein R^1 is methyl, R^2, R^4, and R^5 are hydrogen, and R^3 is indol-4-yl, namely


This Sheet Has Been Replaced

THIS SHEET HAS BEEN REPLACED

2-amino-4-(1H-indol-4-yl)-6-methylpyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

15. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of Claims 1 to 14 in admixture with one or more pharmaceutically acceptable non-toxic carriers.

16. A process for preparing a compound of the formulaI :



wherein:

R^1 is hydrogen, alkyl, hydroxyalkyl, cycloalkyl, cycloalkyl lower alkyl, alkenyl, lower thioalkoxy, halo, fluoroalkyl, optionally substituted phenyl, optionally substituted phenyl lower alkyl, $-NR^6R^7$, $-CO_2R^8$, or $-O(CH_2)_nR^9$, in which

n is 1, 2, or 3;

R^6 and R^7 are hydrogen or lower alkyl;

R^8 is hydrogen or lower alkyl; and

R^9 is hydrogen, lower alkyl, hydroxy, hydroxy lower alkyl, lower alkenyl, or lower alkoxy;

R^2 is hydrogen, lower alkyl, lower alkoxy, halo, or lower fluoroalkyl;

R^3 is optionally substituted aryl;

R^4 is hydrogen, lower alkyl, optionally substituted phenyl-lower alkyl, hydroxy lower alkyl, acyl, $-(CH_2)_mNR^6R^7$, or $-SO_2R^{10}$; in which

m is an integer of 1-6;

and

This Sheet Has Been Replaced

R^{10} is lower alkyl; and

R^5 is hydrogen or lower alkyl;

provided that:

when R^3 is naphthyl, pyridyl, thienyl, indol-1-yl, 2,3-dihydroindol-1-yl, or furanyl, and R^3, R^4 and R^5 are all hydrogen, R^1 is not methyl;


when R^3 is phenyl or naphthyl, R^1 is not $-NR^6R^7$;

when R^3 is naphthyl, R^1 is not phenyl; and

when R^3 is 1,2,3,4-tetrahydroquinolinyl, R^4 and R^5 are hydrogen;


and the pharmaceutically acceptable salts and N-oxides thereof; which process comprises:

(a) reacting a compound of formula (4):



where R^1 and R^2 are as defined with respect to formula I, and R^4 and R^5 are hydrogen or lower alkyl with a boronic acid derivative of formula (5), i.e., $R^3B(OH)_2$ where R^3 is as defined with respt of formula I, to form a compound of formula I where R^1, R^2 and R^3 are as defined, and R^4 and R^5 are hydrogen or lower alkyl; or

(b) reacting a compound of formula (4):




This Sheet Has Been Replaced


THIS SHEET HAS BEEN REPLACED

where R^1 and R^2 are as defined with respect to formula I and R^4 and R^5 are hydrogen or lower alkyl with a boron complex of formula (7), i.e., $R^3B(OCH_3)_2$ where R^3 is as defined with respect to formula I to form a compound of formula I where R^1, R^2 and R^3 are as defined and R^4 and R^5 are hydrogen or lower alkyl; or

(c) reacting a compound of formula (4):




where R^1 and R^2 are as defined with respect to formula I and R^4 and R^5 are hydrogen or lower alkyl with a compound of formula (8):



where Y is CH_2, O, S or NH, and n is 0, 1 or 2, to form a compound of formula I where R^1 and R^2, are as defined, R^3 is a bicyclic ring system containing N as a point of attachment to the pyrimidine nucleus, and R^4 and R^5 are hydrogen or lower alkyl; or

(d) reacting a compound of formula (11):




where R^1, R^2 and R^3 are as defined with a compound of formula (2) i.e., $NH_2C(:NH)NR^4R^5$ where R^4 and R^5 are as defined with respect to formula I to form a compound of formula I where R^1, R^2, R^3, R^4 and R^5 are as defined; or

This Sheet Has Been Replaced


THIS SHEET HAS BEEN REPLACED

(e) reacting a compound of formula (13):




where R^2 and R^3 are as defined with respect to formula I with a compound of formula (2) i.e., $NH_2C(:NH)NR^4R^5$ where R^4 and R^5 are as defined with respect to formula I to form a compound of formula I where R^1 is hydrogen, and R^2, R^3, R^4 and R^5 are as defined; or

(f) reacting a compound of formula (19):



where R^2 and R^3 are as defined with a compound of formula (2) i.e., $NH_2C(:NH)NR^4R^5$, to form a compound of formula I where R^1 is SCH_3, and R^2, R^3, R^4 and R^5 are as defined; or

(g) reacting a compound of formula I where R^1 is chloro:



where R^2 and R^3 are as defined with respect to formula I and R^4 and R^5 are hydrogen or lower alkyl with

i) a reducing agent to give a compound of formula I where R^1 is hydrogen, R^2 and R^3 are as defined and R^4 and R^5 are hydrogen or lower alkyl; or


ii) a secondary amine of formula HNR^6R^7, where R^6 and R^7 are as defined with respect to formula I to

This Sheet Has Been Replaced

THIS SHEET HAS BEEN REPLACED

form a compound of formula I where R^1 is $-NR^6R^7$, and R^2 and R^3 are as defined and R^4 and R^5 are hydrogen or lower alkyl; or

(h) reacting a compound of the formula:



where R^1, R^2 and R^3 are as defined with respect to formula I with a secondary amine of formula HNR^4R^5, where R^4 and R^5 are as defined with respect to formula I to form a compound of formula I, where R^1, R^2, R^3, R^4 and R^5 are as defined; or

(i) reacting an N-oxide of a compound of formula I where R^1 is alkyl with a carboxylic anhydride to give a compound of formula I where R^1 is hydroxyalkyl or alkenyl; and optionally followed by

(j) reacting a compound of formula I with an oxidizing agent to give an N-oxide of a compound of formula I; or

(k) reacting a compound of formula I with a strong acid to give a pharmaceutically acceptable salt of a compound of formula I.

17. A compound as claimed in any one of claims 1 to 14 whenever prepared by the process of claim 16.

18. A compound as claimed in any one of claims 1 to 14 as a therapeutic agent.

19. The use of a compound as claimed in any one of claims 1 to 14 for the preparation of a medicament for the treatment of a disease state selected from the group:

This Sheet Has Been Replaced

THIS SHEET HAS BEEN REPLACED

generalized anxiety disorder, panic disorder, obsessive compulsive disorder, alcoholism, depression, migraine, hypertension, sleep disorders, anorexia nervosa, and priapism.

20. The invention as hereinbefore described.

21. A method for treating a mammal having a disease state which is alleviable by treatment with a $5HT_{2B}$ antagonist, which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound as claimed in any one of claims 1 to 14.

***

This Sheet Has Been Replaced

The present invention relates to aryl pyrimidine derivatives, and pharmaceutically acceptable salts and N-oxides thereof, which exhibit useful pharmacological properties, including utility as selective $5HT_{2B}$-antagonists. The invention is also directed to formulations thereof and their use for the treatment of diseases.

Serotonin, a neurotransmitter with mixed and complex pharmacological characteristics, was first discovered in 1948, and subsequently has been the subject of substantial research. Serotonin, also referred to as 5-hydroxy-tryptamine (5-HT), acts both centrally and peripherally on discrete 5-HT receptors. Currently, fourteen subtypes of serotonin receptor are recognized and delineated into seven familes, 5-HT_1 to 5-HT_7. Within the 5-HT_2 family, 5-HT_{2A}, 5-HT_{2B} and 5-HT_{2C} subtypes are known to exist. These subtypes share sequence homology and display similarities in their specificity for a wide range of ligands. The nomenclature and classification of 5-HT receptors has been reviewed recently by Martin and Humphrey, *Neuropharm.*, 33, 261-273 (1994) and Hoyer *et al.*, *Pharm. Rev.*, 46, 157-203 (1994) and Hoyer et al., Pharm. Rev., 46, 157-203 (1994). Mokrosz et al. determined the 5-HT_{1A} and the 5-HT_{2A} receptor affinity of model 1-(2-pyrimidinyl)piperazine deravatives. (Mokrosz, J.L., et al., Pharmazie, (1994), 49, 801-810).

5-HT_{2B} receptors, initially termed 5-HT_F or serotonin-like receptor, were first characterized in rat isolated stomach fundus [Clineschmidt *et al.* (1985), *J. Pharmacol. Exp. Ther.*, **235**, 696-708; Cohen and Wittenauer, (1987), *J. Cardiovasc. Pharmacol.*, **10**, 176-181].

AB/So 14.4.97


AMENDED SHEET

THIS SHEET HAS BEEN REPLACED

Commun., **26**, 2865-2870 (1961), disclose 2-amino-6-methyl-4-(naphth-1-yl)-pyrimidine as an intermediate useful in the preparation of antibacterial compounds.

Further examples of these compounds are described in WO-A-8500603, WO-A-8500604, WO-A-8604583, WO-A-8907599, WO-A-8911279, US-A-3965101, DE-A-1921049, DE-A-3029871, DE-A-2750288, DE-A-4237768, WO-A-9632384, EP-A-0459830, DE-A-2255525 and EP-A-0114770. Additionally, WO-A-9639400 discloses pyrimidine derivatives that are CRF receptor antagonists. Other pyrimidine derivatives are described in Mariella *et al.*, *J. Org. Chem.*, 25, 647-648 (1960); Zagulyaeva *et al.*, *Izv. Sib. Otd. Akad. Nauk SSSR, Ser. Khim. Nauk*, **4**, 27-31 (1990); Essawy *et al.*, *Egypt. J. Chem.*, 37(4), 423-31 (1994); U.S. Patents Nos. 4,543,248, 4,619,933, 4,665,077, 5,002,951, 5,147,876 and 5,223,505, and European Patent Publication No. [EP] 459 830; EP-A-0210044; A-0521471.

One aspect of the invention concerns compounds represented by formula I:



I

wherein:

R^1 is hydrogen, alkyl, hydroxyalkyl, cycloalkyl, cycloalkyl lower alkyl, alkenyl, lower thioalkoxy, halo, fluoroalkyl, optionally substituted phenyl lower alkyl, $-NR^6R^7$, $-CO_2R^8$, $-O(CH_2)_nR^9$, in which

n is 1, 2, or 3;

R^6 and R^7 are independently hydrogen or lower alkyl;

R^8 is hydrogen or lower alkyl; and

This Sheet Has Been Replaced



AMENDED SHEET

R^9 is hydrogen, lower alkyl, hydroxy, hydroxy lower alkyl, lower alkenyl, or lower alkoxy;

R^2 is hydrogen, lower alkyl, lower alkoxy, halo, or lower fluoroalkyl;

R^3 is optionally substituted aryl other than pyridyl, thienyl, or furanyl;

R^4 is hydrogen, lower alkyl, optionally substituted phenyl-lower alkyl, hydroxy lower alkyl, acyl, or $-(CH_2)_mNR^6R^7$; in which

m is an integer of 1-6; and

R^6 and R^7 are hydrogen or lower alkyl; and

R^5 is hydrogen or lower alkyl;

provided that:

(i) when R^3 is naphthyl, indol-1-yl, or 2,3-dihydroindol-1-yl, and R^2, R^4 and R^5 are all hydrogen, R^1 is not methyl;

(ii) when R^3 is phenyl or naphthyl, R^1 is not $-NR^6R^7$;

(iii) when R^3 is phenyl, R^2 is not lower alkoxy, and R^1 and R^2 are not halo;

(iv) when R^3 is phenyl and R^1 is H, R^2 is not methyl; and

(v) when R^3 is 1,2,3,4-tetrahydroquinolinyl, R^4 and R^5 are hydrogen;

or a pharmaceutically acceptable salt or N-oxide thereof.

AMENDED SHEET

In another aspect, the invention relates to pharmaceutical compositions containing a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or N-oxide thereof, in admixture with one or more pharmaceutically acceptable, non-toxic carriers.

In yet another aspect, the invention relates to a method for treating a mammal having a disease state which is alleviable by treatment with a $5HT_{2B}$ antagonist, by administering to a mammal in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or N-oxide thereof.

The use of a compound of formula I, a pharmaceutically acceptable salt or N-oxide thereof for the preparation of a medicament for the treatment of a disease state which is alleviable by treatment with a $5HT_{2B}$ antagonist is a further object of the present invention.

AMENDED SHEET

2-amino-6-(tert-butyl)-4-(naphth-1-yl)-pyrimidine, m.p. 161.0-161.3°C;

2-amino-6-benzyl-4-(naphth-1-yl)-pyrimidine, m.p. 147.9-148.2°C;

2-amino-6-cyclobutyl-4-(naphth-1-yl)-pyrimidine, m.p. 147-148°C;

2-amino-6-cyclopropyl-4-(naphth-1-yl)-pyrimidine, m.p. 182.8-184.0°C;

2-amino-4-(naphth-1-yl)-6-n-propylpyrimidine, m.p. 119.5-120.5°C;

2-amino-6-isopropyl-4-(naphth-1-yl)-pyrimidine, m.p. 124-126°C;

2-amino-5-fluoro-6-methyl-4-(naphth-1-yl)-pyrimidine, m.p. 155-157°C;

2-amino-6-ethyl-4-(naphth-1-yl)-pyrimidine hydrochloride, m.p. 157-160°C;

2,6-diamino-4-(naphth-1-yl)-pyrimidine hydrochloride, m.p. >290°C;

2-amino-6-trifluoromethyl-4-(naphth-1-yl)-pyrimidine, m.p. 152-154°C;

2-amino-4-(naphth-1-yl)-6-phenylpyrimidine hydrochloride, m.p. 232-236°C;

2-amino-4-(3-fluorophenyl)-6-methylpyrimidine, m.p. 140.6-141.4°C;

2-amino-4-(3-methoxyphenyl)-6-methylpyrimidine, m.p. 125.8-129.6°C;

2-amino-6-methyl-4-(3-nitrophenyl)-pyrimidine, m.p. 196.5-199.6°C;

2-amino-4-(3-chloro-4-fluorophenyl)-6-methylpyrimidine, m.p. 163.8-165.5°C;

2-amino-4-(3,5-dichlorophenyl)-6-methylpyrimidine, m.p. 187.0-187.9°C;

2-amino-6-methyl-4-(3-trifluoromethylphenyl)-pyrimidine, m.p. 122.0-122.8°C;

AMENDED SHEET

EXAMPLE 3

Alternative Preparation of a Compound of Formula I

A. Preparation of I where R^1 is Methyl, R^2 is Hydrogen, R^3 is 6-Methoxy-3,4-Dihydro-2H-Quinolin-1-yl, and R^4 and R^5 are Hydrogen

A flask containing 6-methoxy-1,2,3,4-tetrahydroquinoline (1.33 g), 2-amino-4-chloro-6-methylpyrimidine (1.00 g), sulfuric acid (0.6 g), and 100 ml of water was heated on a steam bath for 2 hours. The solution was then cooled to room temperature and treated with ammonium hydroxide until the solution was basic (pH 8-9). The resultant solid, which precipitated from solution, was collected by filtration and recrystallized from ethyl alcohol to give 2-amino-4-(6-methoxy-3,4,-dihydro-2H-quinolin-1-yl)-6-methylpyrimidine (0.93 g), m.p. 175.2-175.9°C.

B. Similarly, optionally replacing 6-methoxy-1,2,3,4-tetrahydroquinoline with other compounds of formula (8), and optionally replacing 2-amino-4-chloro-6-methylpyrimidine with other compounds of formula (4), and following the procedures of Example 3A above, the following compounds of formula I were prepared:

2-amino-4-(6-fluoro-3,4-dihydro-2H-quinolin-1-yl)-6-methylpyrimidine, m.p. 156-157°C;

2-amino-6-chloro-4-(3,4-dihydro-2H-quinolin-1-yl)-pyrimidine hydrochloride, m.p. >180°C (dec);

2,6-diamino-4-(3,4-dihydro-2H-quinolin-1-yl)-pyrimidine dihydrochloride, m.p. 196-197°C;

6-(3,4-dihydro-2H-quinolin-1-yl)-9H-purin-2-ylamine, m.p. 203.5-204.0°C;

2-amino-4-(2-methyl-3,4-dihydro-2H-quinolin-1-yl)-6-methylpyrimidine, m.p. 141-144°C;

AMENDED SHEET

THIS SHEET HAS BEEN REPLACED

2-amino-4-(6-methoxy-3,4-dihydro-2H-quinolin-1-yl)-6-trifluoromethylpyrimidine, m.p. 175.6-177.5°C;

2-amino-4-(3,4-dihydro-2H-quinolin-1-yl)-6-ethylpyrimidine, m.p. 141.4-142.1°C;

2-amino-6-methyl-4-(6-methyl-3,4-dihydro-2H-quinolin-1-yl)-pyrimidine, m.p. 170.6-171.4°C;

2-amino-4-(3,4-dihydro-2H-quinolin-1-yl)-6-trifluoromethylpyrimidine, m.p. 162-164°C;

2-amino-4-(6-fluoro-2-methyl-3,4-dihydro-2H-quinolin-1-yl)-6-methylpyrimidine, m.p. 154.9-155.6°C;

4-(3,4-dihydro-2H-quinolin-1-yl)-2-(methylamino)-pyrimidine ;

[2-(3,4-dihydro-2H-quinolin-1-yl)-pyrimidin-4-yl]methylamine;

2-amino-6-methyl-4-(2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-pyrimidine, m.p. 182.6-184.2°C;

2-amino-4-(7,8-dihydro-6H-5-oxa-9-azabenzochyclohepten-9-yl)-6-methylpyrimidine, m.p. 189.9-192.0°C;

2-amino-4-(2,3-dihydro-benzo[1,4]oxazin-4-yl)-6-methylpyrimidine, m.p. 177.7-178.5°C;

2-amino-4-(2-methyl-2,3-dihydro-indol-1-yl)-6-methylpyrimidine, m.p. 182.9-183.4°C;

2-amino-4-(3,4-dihydro-2H-quinolin-1-yl)-6-methylpyrimidine hydrochloride, m.p. 261.5-262.3°C; and

2-amino-4-(3,4-dihydro-1H-isoquinolin-2-yl)-6-methylpyrimidine, m.p. 142.2-143.3°C.

C. Preparation of I where R^1 is Chloro, R^2 is Hydrogen, R^3 is 3,4-Dihydro-2H-Quinolin-1-yl, and R^4 and R^5 are Hydrogen

1,2,3,4,-tetrahydroquinoline (2.66 g, 20 mmol) and 2-amino-4,6-dichloropyrimidine (3.30 g, 20 mmol) were dissolved in 10 ml of N,N-dimethylformamide (DMF), and the entire solution was heated to 70-90°C for 24 hours. DMF was

This Sheet Has Been Replaced

AMENDED SHEET

methyl-4-naphth-1-yl)-pyrimidin-2-ylamino)-pentanoic acid, m.p. 264-266°C was prepared.

D. Similarly, replacing 4-acetylindole with 1-acetylnaphthalene in step 5A, and following the procedures of Example 5A and 5B, the compound 2-amino-6-methyl-4-(naphth-1-yl)-pyrimidine hydrochloride, was prepared.

E. Similarly, replacing 1-(1H-indol-4-yl)-1,3-butanedione with 1-(3-chlorophenyl)-1,3-butanedione and following the procedures of Example 5B above, the compound 2-amino-4-(3-chlorophenyl)-6-methylpyrimidine, m.p. 131.6-132.3°C was prepared.

F. Preparation of I where R^1 is Methyl, R^2 is Hydrogen, R^3 is 2,3-dihydro-1,4-benzodioxin-5-yl, and R^4 and R^5 are Hydrogen

1-(2,3-Dihydro-1,4-benzodioxin-5-yl)-ethanone (1.2 g) was dissolved in 20 ml of ethyl acetate, and sodium hydride (0.33 g, 60% oil dispersion) was added. The reaction mixture was heated to 80°C overnight, quenched with water, and neutralized with carbon dioxide to give an oily product of 1-(2,3-dihydro-1,4-benzodioxin-5-yl)butan-1,3-dione (0.37 g).

The 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-butan-1,3-dione (0.37 g), was mixed with guanidine carbonate (0.22 g), and the mixture was heated to 135°C for 1 hour. The dark product was taken up in methylene chloride, filtered, and concentrated. The residue was chromatographed on silica gel, eluting with a 3:2 mixture of ethyl acetate/hexane, to give a solid (0.16 g), which was treated with hydrochloric acid-ethanol to give 2-amino-4-(2,3-dihydro-1,4-benzodioxin-5-yl)-6-methylpyrimidine hydrochloride (0.125 g), m.p. 240-242°C.

AMENDED SHEET

4-(4-fluoronaphth-1-yl)-6-isopropyl-2-methylamino-pyrimidine, m.p. 115-116°C;

4-(4-fluoronaphth-1-yl)-6-(2-hydroxy-2-phenethyl)-2-methylaminopyrimidine, m.p. 138.1-139.2°C;

4-(4-fluoronaphth-1-yl)-6-phenethyl-2-methylamino-pyrimidine hydrochloride, m.p. 130.7-131.2°C;

4-(4-fluoronaphth-1-yl)-2-isopropylamino-6-methoxypyrimidine hydrochloride, m.p. 191.3-191.6°C;

2-(dimethylamino)ethylamino-4-(4-fluoronaphth-1-yl)-6-isopropypyrimidine hydrochloride, m.p. 176.5°C;

4-(4-fluoronaphth-1-yl)-6-isopropy-2-(methylamino)-ethylamino-pyrimidine hydrochloride, m.p. 152-153°C;

4-(4-fluoronaphth-1-yl)-6-(2-hydroxypropyl)-2-(methylamino)-ethylamino-pyrimidine hydrochloride, m.p. 125-130°C;

2-(2-hydroxyethyl)amino-4-(4-fluoronaphth-1-yl)-6-methoxypyrimidine hydrochloride, m.p. 191.3-191.6°C;

6-*tert*-butyl-4-(4-fluoronaphth-1-yl)-2-methylamino-pyrimidine, m.p. 129.4-130.0°C;

2-benzylamino-6-*tert*-butyl-4-(4-fluoronaphth-1-yl)-pyrimidine, m.p. 106.2-106.9°C;

6-*tert*-butyl-4-(4-fluoronaphth-1-yl)-2-isopropylamino-pyrimidine hydrobromide, m.p. 196.5-197.2°C;

6-*tert*-butyl-4-(4-fluoronaphth-1-yl)-2-(2-methoxy-ethyl)amino-pyrimidine hydrochloride, m.p. 114.5-117.8°C;

4-(4-fluoronaphth-1-yl)-6-isopropyl-2-(pyridin-4-yl)methylamino-pyrimidine, m.p. 149.1-149.5°C;

2-(2-amino)ethylamino-4-(4-fluoronaphth-1-yl)-6-isopropyl-pyrimidine fumarate, m.p. 172.4-172.6°C;

4-(4-fluoronaphth-1-yl)-6-isopropyl-2-(4-methoxy-phenyl)methylamino-pyrimidine hydrochloride, m.p. 65-67°C;

4-(4-fluoronaphth-1-yl)-2-(tetrahydro-2-furyl)methyl-amino-6-isopropyl-pyrimidine, m.p. 72.7-73.8°C;

4-(4-fluoronaphth-1-yl)-2-(2-hydroxy)ethylamino-6-isopropyl-pyrimidine maleate, m.p. 101.9-104.1°C;

AMENDED SHEET

4-(4-fluoronaphth-1-yl)-2-(2-hydroxyethoxy)ethylamino-6-isopropyl-pyrimidine hydrobromide, m.p. 115.3-116.7°C;

2-(1,3-dihydroxyprop-2-yl)amino-4-(4-fluoronaphth-1-yl)-6-isopropyl-pyrimidine maleate, m.p. 125.3-126.6°C;

2-amino-4-(4-fluoronaphth-1-yl)-6-(2-methoxy)ethyl-pyrimidine maleate, m.p. 94-100°C; and

2-amino-4-(4-fluoronaphth-1-yl)-6-phenethylpyrimidine maleate, m.p. 145-146°C.

C. Similarly, optionally replacing ethylamine with other amines of formula NHR^4R^5 and optionally replacing 4-(4-fluoronaphth-1-yl)-6-isopropyl-2-methylsulfonylpyrimidine with other compounds of formula (18), and following the procedures of Example 8A above, other compounds of formula I are prepared.

EXAMPLE 9

Preparation of an N-oxide of a Compound of Formula I

A. Preparation of The N-Oxide of a Compound of Formula I where R^1 is Methyl, R^2 is Hydrogen, R^3 is Naphth-1-yl, and R^4 and R^5 are Hydrogen

2-Amino-6-methyl-4-(naphth-1-yl)-pyrimidine (0.28 g) was dissolved in 15 ml of chloroform at 0°C. m-Chloroper-

AMENDED SHEET

benzoic acid (0.54 g) was added to the solution in portions over 5 minutes. After complete addition, the solution was warmed to 40°C for 30 minutes. The solution was washed with 10% aqueous sodium thiosulfate, 1M sodium hydroxide, and water. The chloroform layer was dried (sodium sulfate) and concentrated; the solid residue was recrystallized from ethyl alcohol-diethyl ether to give 2-amino-6-methyl-4-(naphth-1-yl)-pyrimidine-1-N-oxide (0.07 g), m.p. 228.7-229.5°C.

B. Similarly, replacing 2-amino-6-methyl-6-(naphth-1-yl)-pyrimidine with other compounds of formula I, and following the procedures of Example 9A above, the following N-oxides of compounds of formula I were prepared:

2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-3-N-oxide, m.p. 188-189°C;

2-amino-6-tert-butyl-4-(4-fluoronaphth-1-yl)-pyrimidine-3-N-oxide, m.p. 188.6-190.9°C;

2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-1-N-oxide hydrochloride, m.p. 207-208°C;

2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-1-N-oxide, m.p. 153-155°C;

2-acetylamino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-1-N-oxide, ^{1}HNMR (200 MHz), J 1.39 (d,6h), 2.51(s,3H), 3.81(m,1H), 7.21-7.27(m,2H), 7.62-7.68(m,3H), 8.10-8.23(m,1H), 8.38-8.41(m,1H); and

4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-2-methylamino-1-N-oxide, m.p. 181-182.5°C.

C. Similarly, replacing 2-amino-6-methyl-4-(naphth-1-yl)-pyrimidine with other compounds of formula I and following

AMENDED SHEET

EXAMPLE 11

Preparation of a Compound of Formula I from Other Compounds of Formula I

A. Preparation of a Compound of Formula I where R^4 is acetyl, and R^5 is Hydrogen

2-Amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine (0.5 g) was dissolved in acetic anhydride (10 ml) and 4-dimethylaminopyridine (0.125 g) was added. The reaction mixture was stirred overnight at room temperature, then heated at 75° to 80°C for a total of 4 hours, and evaporated to dryness under vacuum. The residue was partitioned between water and ethyl acetate and then dried over magnesium sulfate. The diacetyl compound was isolated as an oil by evaporation and then dissolved in methanol (20 ml). The solution was treated with saturated sodium bicarbonate solution (2 ml) and allowed to stir overnight. The resulting monoacetyl derivative was isolated by evaporation to dryness and thorough drying under vacuum. The residue was taken up in boiling hexane and decanted from a small amount of insoluble residue and crystallized to yield 2-acetylamino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine, m.p. 115.4-116.7°C.

AMENDED SHEET

B. Preparation of a Compound of Formula I where R^4 is Phenylaminocarbonyl, and R^5 is Hydrogen

2-Amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine (288.3 mg) was dissolved in benzene (50 ml) and phenylisocyanate (119.1 mg) was added. The reaction mixture was heated to reflux for 48 hours, and the solvent was removed under vacuum. The residue was chromatographed on silica gel, eluting with 80:20 hexane:ethyl acetate, to yield 4-(4-fluoronaphth-1-yl)-6-isopropyl-2-phenylureido-pyrimidine (49.1 mg, m.p. 117-178).

AMENDED SHEET

EXAMPLE 12

This example illustrates the preparation of a representative pharmaceutical formulation for oral administration containing an active compound of formula I, *e.g.*, 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine.

Ingredients	Quantity per tablet, mgs.
Active Compound	200
Lactose, spray-dried	148
Magnesium stearate	2

The above ingredients are mixed and introduced into a hard-shell gelatin capsule.

Other compounds of formula I, such as those prepared in accordance with Examples 1-10, can be used as the active compound in the preparation of the orally administrable formulations of this example.

EXAMPLE 13

This example illustrates the preparation of another representative pharmaceutical formulation for oral administration containing an active compound of formula I, *e.g.*, 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine.

Ingredients	Quantity per tablet, mgs.
Active Compound	400
Cornstarch	50
Lactose	145
Magnesium stearate	5

AMENDED SHEET

The above ingredients are mixed intimately and pressed into single scored tablets.

Other compounds of formula I, such as those prepared in accordance with Examples 1-10, can be used as the active compound in the preparation of the orally administrable formulations of this example.

EXAMPLE 14

This example illustrates the preparation of a representative pharmaceutical formulation containing an active compound of formula I, *e.g.*, 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine.

An oral suspension is prepared having the following composition.

Ingredients		
Active Compound	1.0	g
Fumaric acid	0.5	g
Sodium chloride	2.0	g
Methyl paraben	0.1	g
Granulated sugar	25.5	g
Sorbitol (70% solution)	12.85	g
Veegum K (Vanderbilt Co.)	1.0	g
Flavoring	0.035	ml
Colorings	0.5	mg
Distilled water	q.s. to 100	ml

Other compounds of formula I, such as those prepared in accordance with Examples 1-10, can be used as the active compound in the preparation of the orally administrable formulations of this example.

AMENDED SHEET

EXAMPLE 15

This example illustrates the preparation of a representative pharmaceutical formulation for oral administration containing an active compound of formula I, *e.g.*, 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine.

An injectable preparation buffered to a pH of 4 is prepared having the following composition:

Ingredients	
Active Compound	0.2 g
Sodium Acetate Buffer Solution (0.4 M)	2.0 ml
HCl (1N)	q.s. to pH 4
Water (distilled, sterile)	q.s. to 20 ml

Other compounds of formula I, such as those prepared in accordance with Examples 1-10, can be used as the active compound in the preparation of the injectable formulations of this example.

EXAMPLE 16

This example illustrates the preparation of a representative pharmaceutical formulation for topical application containing an active compound of formula I, *e.g.*, 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine.

Ingredients	grams
Active compound	0.2-10
Span 60	2
Tween 60	2
Mineral oil	5
Petrolatum	10
Methyl paraben	0.15

AMENDED SHEET

Propyl paraben	0.05
BHA (butylated hydroxy anisole)	0.01
Water	q.s. to 100

All of the above ingredients, except water, are combined and heated to 60°C with stirring. A sufficient quantity of water at 60°C is then added with vigorous stirring to emulsify the ingredients, and water then added q.s. 100 g.

Other compounds of formula I, such as those prepared in accordance with Examples 1-10, can be used as the active compound in the preparation of the topical formulations of this example.

EXAMPLE 17

This example illustrates the preparation of a representative pharmaceutical formulation containing an active compound of formula I, *e.g.*, 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine.

A suppository totalling 2.5 grams is prepared having the following composition:

Ingredients	
Active Compound	500 mg
Witepsol H-15*	balance

(* triglycerides of saturated vegetable fatty acid; a product of Riches-Nelson, Inc., New York, N.Y.)

Other compounds of formula I, such as those prepared in accordance with Examples 1-10, can be used as the active compound in the preparation of the suppository formulations of this example.

AMENDED SHEET

EXAMPLE 18

Cloned Rat 5-HT2B Receptor Binding Assay

The following describes an *in vitro* binding assay utilizing cloned 5-HT_{2B} receptors radiolabelled with [^{3}H]-5HT.

Mouse NIH3T3 fibroblasts expressing cloned 5-HT_{2B} receptor were maintained in Dulbecco's Modified Eagle medium with 10% Fetal Calf Serum and 250 µg/ml G418 in 95/5% O_2/CO_2. The cells were harvested using 2 mM EDTA in phosphate buffered saline (calcium/magnesium free) and centrifuged (500 g). The cell pellet was homogenized using a Polytron P10 disrupter (setting 5, 5 sec) in homogenization buffer (Tris, 50 mM; Na_2EDTA, 5 mM) and the homogenate was centrifuged at 19,500 rpm using a Sorvall/Dupont RC5C centrifuge with an SS34 rotor (30,000-48,000 g, 15 minutes). The pellet was homogenized (setting 5, 5 sec) in homogenization buffer and the homogenate was centrifuged (30,000-48,000 g, 15 minutes). The pellet was homogenized (setting 5, 5 sec) in resuspension buffer (Tris, 50 mM; EDTA 0.5 mM) and the homogenate was centrifuged (30,000-48,000 g, 15 minutes). The pellet was homogenized (setting 5, 5 sec) in a small volume of resuspension buffer to give approximately $1.5x10^8$ cells/ml. The membranes were separated into 1 ml aliquots and stored at -70°C.

The membranes were thawed at room temperature and diluted with assay buffer calcium chloride$\xi 2H_2O$, 4.5 mM; Tris, 50 mM; 0.1% ascorbic acid). Specific binding is at least 90% of total binding with $1.5x10^6$ cells per assay tube. The membranes were homogenized (setting 5, 5 sec) and then the homogenate was added to assay tubes containing [^{3}H]-5HT ($2x10^{-10}$M) test compound ($1x10^{-10}$-$1x10^{-4}$M) and assay buffer (q.s. to 500 µλ). The assay mixture was

AMENDED SHEET

incubated at 40°C for 2 hours and then filtered over 0.1% polyethyleneimine pre-treated glass fiber filtermats using a Brandel cell harvester. The assay tubes were rinsed with cold assay buffer and dried by drawing air over the filter for 10 seconds. Radioactivity retained on the filters was determined by liquid scintillation counting. For each compound tested the concentration producing 50% inhibition of binding (IC_{50}) was determined using iterative curve fitting techniques.

Proceeding as in Example 17, compounds of the invention were found to have affinity for the 5-HT_{2B} receptor.

EXAMPLE 19

5-HT_{2A} 5-HT_{2B} 5-HT_{2C} Receptor Binding Methods

The following describes receptor binding methods in which ligands with high affinity for 5-HT_{2B} receptors were counter screened at 5-HT_{2A} and 5-HT_{2C} receptors to demonstrate selectivity.

5-HT_{2A} receptors were labelled with [^{3}H]ketanserin in human cortex, in Cos-7 cells expressing a cloned human 5-HT_{2A} receptor and in NIH-3T3 cells expressing the rat 5-HT_{2A} receptor. For competition binding studies the ligand concentration was approximately 0.1 nM. For saturation binding studies concentrations of radioligand ranged from 0.01 nM to 2.0 nM. Assays were conducted in 0.5 ml of assay buffer containing 50 mM Tris-HCl, 4 mM calcium chloride, and 0.1% ascorbic acid (pH 7.4 at 4°C). Non-specifc binding was defined with 10 mM unlabelled ketanserin. After a 60 minute incubation at 32°C, membranes were harvested onto filters treated with 0.1% polyethylenimine and the bound radioactivity was determined.

AMENDED SHEET

Human 5-HT_{2B} receptors were labelled in Cos-7 cells as described above except that the radioligand was [^{3}H]5-HT and that the assay buffer contained 10 mM pargyline and 0.1% ascorbic acid. For competition binding studies the radioligand concentration was approximately 0.4 nM while for saturation binding studies the concentration of [^{3}H]5-HT ranged from 0.05 to 8 nM. Non-specific binding was defined with 10 mM 5-HT. Incubations were for 120 minutes at 4°C.

5-HT_{2C} receptors were labelled in choroid plexus, Cos-7 cells expressing the human 5-HT_{2C} receptor and in NIH-3T3 expressing the rat 5-HT_{2C} receptor. Assays were conducted as described for the 5-HT_{2A} receptor except that the radioligand was [^{3}H]mesulergine. The radioligand concentration for competition studies was approximately 0.2 nM while for saturation binding studies the concentration ranged from 0.1 to 18 nM. Non-specific binding was defined with 10 µM unlabelled mesulergine.

Competition radioligand binding data was analyzed using a four parameter logistic equation and iterative curve-fitting techniques to obtain estimates of the IC_{50} and Hill slope. Kd values, determined from saturation binding studies were then used to calculate inhibition dissociation constants (Ki).

Proceeding as in Example 18, compounds of the invention were found to have affinity for the 5-HT_{2B} receptor.

EXAMPLE 20

5-HT_{2B} Receptor Tissue Based Functional Assay

The following describes an *in vitro* functional assay characterizing 5-HT receptors (the putative 5-HT_{2B}) in rat stomach fundus longitudinal muscle.

AMENDED SHEET

The rat stomach fundus was set up as described by Baxter *et al.*, (1994), *Brit. J. Pharmacol.*, 112, 323-331. Strips of longitudinal muscle were obtained from the stomach fundus of male Sprague Dawley rats. The mucosa was removed and the strips were suspended with a resting tension of 1 gram in oxygenated Tyrode solution. The temperature was maintained at 37°C, and the experiments were conducted in the presence of pargyline (100 μM).

To test for antagonist actions concentration-response curves to 5-HT were generated in the presence or absence of the putative antagonist. Shild plots were generated to determine the affinity of the antagonist. To test for agonist the actions of the test compound alone, on the isolated tissue strip were quantified.

The compounds of the present invention were found to be antagonists at the 5-HT_{2B} receptor when tested by this method.

EXAMPLE 21

Anxiolytic Behavior Assay

The following describes an *in vivo* method for determining anxiolytic activity by measuring the extent the drug affects the natural anxiety of mice when exposed to a novel, brightly lighted environment.

Naive male C5BI/6J mice, 18-20 g, are kept in groups of 10 mice in quarters controlled for sound, temperature and humidity. Food and water are available ad libitum. The mice are kept on a 12 hour light and 12 hour dark cycle, with lights on at 6:00 a.m. and off at 6:00 p.m. All experiments begin at least 7 days after arrival on site.

AMENDED SHEET

EXAMPLE 22

Withdrawal Anxiety Assay

The following describes an *in vivo* procedure for determining amelioration of the symptoms caused by withdrawal from addictive substances by measuring the extent the drug affects the anxiety that occurs in mice after chronically treating with an addictive substance and then abruptly ceasing the treatments.

Naive male BKW mice (25-30 g) are caged in groups of ten in quarters controlled for sound, temperature and humidity. Food and water are available ad libitum. The mice are kept on a 12 hour light cycle and 12 hour dark cycle, with lights on at 6:00 a.m. and off at 6:00 p.m. All experiments begin at least 7 days after arrival on site.

Levels of anxiety are determined by the two-compartment exploratory model of Crawley and Goodwin (see Example 14). Anxiolysis is seen as a general increase in exploratory activity in the lighted area. An increase in exploratory activity is reflected by increased latency (the time for the mouse to move to the dark chamber when first placed in the center of the lighted area), increased or unaltered locomotor activity (number of grid lines crossed), increased number of rears and decreased time spent in the dark compartment.

Increased exploratory activity in the lighted area is induced by treating the mice for 14 days with ethanol (8.0 % w/v in drinking water), nicotine (0.1 mg/kg, i.p., twice daily) or cocaine (1.0 mg/kg, i.p., twice daily). Anxiolysis is assessed 1, 3, 7 and 14 days after commencement of the drug regime. The treatment is abruptly ceased and exploratory activity in the lighted area is determined 8, 24 and 48 hours thereafter. Vehicle or test


AMENDED SHEET

* C L M S *

CLAIMS

THIS SHEET HAS BEEN REPLACED

1. A compound of the formula I:



wherein said compound is a 5-HT_{2B} receptor antagonist, and further wherein:

R^1 is hydrogen, C_1-C_{12}-alkyl, hydroxy-C_1-C_{12}-alkyl, C_3-C_8-cycloalkyl, C_3-C_8-cycloalkyl-C_1-C_6-alkyl, C_2-C_{12}-alkenyl, C_1-C_6-thioalkoxy, halo, fluoro-C_1-C_{12}-alkyl, phenyl-C_1-C_6-alkyl, optionally substituted by C_1-C_6-alkyl, C_1-C_6-alkoxy, hydroxy, nitro, C_1-C_6-fluoroalkyl and halo; $-NR^6R^7$, $-CO_2R^8$ or $-O(CH_2)_nR^9$, in which

n is 1, 2, or 3;

R^6 and R^7 are independently hydrogen or C_1-C_6-alkyl;

R^8 is hydrogen or C_1-C_6-alkyl; and

R^9 is hydrogen, C_1-C_6-alkyl, hydroxy, hydroxy-C_1-C_6-alkyl, C_2-C_6-alkenyl, or C_1-C_6-alkoxy;

R^2 is hydrogen, C_1-C_6-alkyl, C_1-C_6-alkoxy, halo, or C_1-C_6-fluoroalkyl;

R^3 is phenyl, thiophene, naphthalene, anthracene, phenanthrene, quinoline, isoquinoline, 1,2,3,4-tetrahydroquinoline, indole, 2,3-dihydroindole, 1H-benzo[b]azepine, 2,3,4,5-tetrahydro-1H-benzo[b]azepine, 2H-benzo[1,4]oxazine, 3,4-dihydro-2H-benzo[1,4]oxazine, 1H,3H-benzo[de]isochromene, 6,7,8,9-tetrahydro-5-oxa-9-benzocycloheptane, 2,3-dihydro-1,4-benzodioxane , optionally substituted by C_1-C_6-alkyl, C_1-C_6-alkoxy, hydroxy, nitro, C_1-C_6-fluoroalkyl and halo;

This Sheet Has Been Replaced

AMENDED SHEET

* C L M S *

THIS SHEET HAS BEEN REPLACED

R^4 is hydrogen, C_1-C_6-alkyl, phenyl-C_1-C_6-alkyl, optionally substituted by C_1-C_6-alkyl, C_1-C_6-alkoxy, hydroxy, nitro, C_1-C_6-fluoroalkyl and halo; hydroxy-C_1-C_6-alkyl, C(O)-C_1-C_6-alkyl, or $-(CH_2)_mNR^6R^7$; in which

m is an integer of 1-6; and

R^6 and R^7 are hydrogen or l C_1-C_6-alkyl; and

R^5 is hydrogen or C_1-C_6-alkyl;

provided that:

(i) when R^3 is naphthyl, indol-1-yl, or 2,3- dihydroindol-1-yl, and R^2, R^4 and R^5 are all hydrogen, R^1 is not methyl;

(ii) when R^3 is phenyl or naphthyl, R^1 is not $-NR^6R^7$;

(iii) when R^3 is phenyl, R^2 is not C_1-C_6-alkoxy, and R^1 and R^2 are not halo;

(iv) when R^3 is phenyl and R^1 is H, R^2 is not methyl; and

(v) when R^3 is 1,2,3,4-tetrahydroquinolinyl, R^4 and R^5 are hydrogen;

or a pharmaceutically acceptable salt or N-oxide thereof.

2. The compound of Claim 1, wherein R^4 and R^5 are hydrogen or C_1-C_6-alkyl.

3. The compound of Claim 2, wherein R^1 is C_1-C_6-alkyl, fluoro-C_1-C_{12}-alkyl, or hydroxy-C_1-C_{12}-alkyl, and R^3 is 1-naphthyl, optionally substituted by C_1-C_6-alkyl, C_1-C_6-alkoxy, hydroxy, nitro, C_1-C_6-fluoroalkyl and halo;

or a pharmaceutically acceptable salt or N-oxide thereof.

4. The compound of Claim 3, wherein R^1 is methyl, R^2, R^4, and R^5 are hydrogen, and R^3 is 2- methylnaphth-1-yl, namely 2-amino-4-(2-methylnaphth-1-yl)-6-methylpyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

5. The compound of Claim 3, wherein R^1 is isopropyl, R^2, R^4, and R^5 are hydrogen, and R^3 is 4- fluoronaphth-1-yl, namely 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropyl-pyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

This Sheet Has Been Replaced

AMENDED SHEET

* C L M S *

THIS SHEET HAS BEEN REPLACED

6. The compound of Claim 5, wherein the N-oxide is at the 1-position, namely 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-l-N-oxide.

7. The compound of Claim 3, wherein R^1 is 1- fluoro-1-methylethyl, R^2, R^4, and R^5 are hydrogen, and R^3 is 4-fluoronaphth-1-yl, namely 2-amino-4-(4-fluoronaphth-1-yl)-6-(1-fluoro-l-methylethyl)- pyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

8. The compound of Claim 3, wherein R^1 is 1- hydroxy-1-methylethyl, R^2, R^4, and R^5 are hydrogen, and R^3 is 4-fluoronaphth-1-yl, namely 2-amino-4-(4-fluoronaphth-1-yl)-6-(1-hydroxy-l-methylethyl)-pyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

9. The compound of Claim 3, wherein R^1 is 1- fluoro-1-methylethyl, R^2, R^4, and R^5 are hydrogen, and R^3 is 4,6-difluoronaphth-1-yl, namely 2-amino-4-(4,6-difluoronaphth-l-yl)-6-(l-fluoro-l-methylethyl)-pyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

10. The compound of Claim 3, wherein R^1 is isopropyl, R^2 and R^4 are hydrogen, R^5 is methyl, and R^3 is 4-fluoronaphth-1-yl, namely 2-methylamino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

11. The compound of Claim 3, wherein R^1 is 2- methylpropyl, R^2, R^4, and R^5 are hydrogen, and R^3 is 4- fluoronaphth-1-yl, namely 2-amino-4-(4-fluoronaphth-1-yl)-6-(2-methylpropyl)- pyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

12. The compound of Claim 3, wherein R^1 is tert-butyl, R^2, R^4, and R^5 are hydrogen, and R^3 is 4- fluoronaphth-1-yl, namely 2-amino-6-(tert-butyl)-4-(4-fluoronaphth-1-yl)- pyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

13. The compound of Claim 2, wherein R^1 is C_1-C_6-alkyl and R^3 is optionally substituted indole, or a pharmaceutically acceptable salt or N-oxide thereof.

This Sheet Has Been Replaced

AMENDED SHEET

* C L M S *


THIS SHEET HAS BEEN REPLACED

14. The compound of Claim 13, wherein R^1 is methyl and R^2, R^4 and R^5 are hydrogen, and R^3 is indol-4-yl, namely 2-amino-4-(1H-indol-4-yl)-6-methylpyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

15. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of Claims 1 to 14 in admixture with one or more pharmaceutically acceptable non-toxic carriers.

16. A process for preparing a compound of the formula I:

This Sheet Has Been Replaced



wherein:

R^1 is hydrogen, C_1-C_{12}-alkyl, hydroxy-C_1-C_{12}-alkyl, C_3-C_8-cycloalkyl, C_3-C_8-cycloalkyl-C_1-C_6-alkyl, C_2-C_{12}-alkenyl, C_1-C_6-thioalkoxy, halo, fluoro-C_1-C_{12}-alkyl, phenyl-C_1-C_6-alkyl, optionally substituted by C_1-C_6-alkyl, C_1-C_6-alkoxy, hydroxy, nitro, C_1-C_6-fluoroalkyl and halo; $-NR^6R^7$, $-CO_2R^8$, $-O(CH_2)_nR^9$, in which

n is 1, 2, or 3;

R^6 and R^7 are independently hydrogen or I C_1-C_6-alkyl;

R^8 is hydrogen or C_1-C_6-alkyl; and

R^9 is hydrogen, C_1-C_6-alkyl, hydroxy, hydroxy-C_1-C_6-alkyl, C_2-C_6-alkenyl, or C_1-C_6-alkoxy;

R^2 is hydrogen, C_1-C_6-alkyl, C_1-C_6-alkoxy, halo, or C_1-C_6-fluoroalkyl;

R^3 is phenyl, thiophene, naphthalene, anthracene, phenanthrene, quinoline, isoquinoline, 1,2,3,4-tetrahydroquinoline, indole, 2,3-dihydroindole, 1H-benzo[b]azepine, 2,3,4,5-tetrahydro-1H-benzo[b]azepine, 2H-benzo[1,4]oxazine, 3,4-dihydro-2H-benzo[1,4]oxazine, 1H,3H-benzo[de]isochromene, 6,7,8,9-tetrahydro-5-oxa-9-benzocycloheptane, 2,3-dihydro-1,4-benzodioxane, optionally substituted by C_1-C_6-alkyl, C_1-C_6-alkoxy, hydroxy, nitro, C_1-C_6-fluoroalkyl and halo;

AMENDED SHEET

* C L M S *

THIS SHEET HAS BEEN REPLACED

R^4 is hydrogen, C_1-C_6-alkyl, phenyl-C_1-C_6-alkyl, optionally substituted by C_1-C_6-alkyl, C_1-C_6-alkoxy, hydroxy, nitro, C_1-C_6-fluoroalkyl and halo; hydroxy-C_1-C_6-alkyl, C(O)-C_1-C_6-alkyl, or -$(CH_2)_mNR^6R^7$; in which

m is an integer of 1-6; and

R^6 and R^7 are hydrogen or C_1-C_6-alkyl; and

R^5 is hydrogen or C_1-C_6-alkyl;

provided that:

(i) when R^3 is naphthyl, indol-1-yl, or 2,3- dihydroindol-1-yl, and R^2, R^4 and R^5 are all hydrogen, R^1 is not methyl;

(ii) when R^3 is phenyl or naphthyl, R^1 is not


-NR^6R^7;

(iii) when R^3 is phenyl, R^2 is not C_1-C_6-alkoxy, and R^1 and R^2 are not halo;

(iv) when R^3 is phenyl and R^1 is H, R^2 is not methyl; and

(v) when R^3 is 1,2,3,4-tetrahydroquinolinyl, R^4 and R^5 are hydrogen;

or a pharmaceutically acceptable salt or N-oxide thereof; which process comprises reacting a compound of formula (4)



with a boronic acid derivative of formula (5), i.e., $R^3B(OR^{11})_2$ to form a compound of formula I where R^1, R^2 and R^3 are as defined for formula I, R^4 and R^5 are hydrogen or C_1-C_6-alkyl and R^{11} is H or methyl.


17. A process for preparing a compound of the formula I comprising of reacting a compound of the formula (6)

This Sheet Has Been Replaced

AMENDED SHEET

* C L M S *

THIS SHEET HAS BEEN REPLACED



with a secondary amine of formula NHR^4R^5 to form a compound of formula I, where R^1, R^2, R^3, R^4 and R^5 are as defined for formula I.

18. A process described in claims 16 or 17 further comprising reacting a compound of formula I with an oxidizing agent to give an N-oxide of a compound of formula I.

19. A process described in claim 16 or 17 further comprising reacting a compound of formula I with a strong acid to give a pharmaceutically acceptable salt of a compound of formula I.

20. A process described in claim 18 further comprising reacting an N-oxide of a compound of formula I where R^1 is alkyl with a carboxylic anhydride to give a compound of formula I where R^1 is hydroxyalkyl or alkenyl; optionally followed by reacting a compound of formula I with a strong acid to give a pharmaceutically acceptable salt of a compound of formula I.

21. A compound as claimed in any one of claims 1 to 14 for use as a therapeutic agent.

22. The use of a compound as claimed in any one of claims 1 to 14 for the preparation of a medicament for the treatment of a disease state selected from the group:

generalized anxiety disorder, panic disorder, obsessive compulsive disorder, alcoholism, depression, migraine, hypertension, sleep disorders, anorexia nervosa, and priapism.

23. A method for treating a mammal having a disease state which is alleviable by treatment with a $5HT_{2B}$ antagonist, which comprises

This Sheet Has Been Replaced

AMENDED SHEET

* C L M S *

THIS SHEET HAS BEEN REPLACED

administering to a mammal in need thereof a therapeutically effective amount of a compound as claimed in any one of claims 1 to 14.

This Sheet Has Been Replaced

AMENDED SHEET


REPLACEMENT SHEET
26 MAR 1999

REPLACEMENT SHEET IPOS

Commun., 26, 2865-2870 (1961), disclose 2-amino-6-methyl-4-(naphth-1-yl)-pyrimidine as an intermediate useful in the preparation of antibacterial compounds.

Further examples of these compounds are described in WO-A-8500603, WO-A-8500604, WO-A-8604583, WO-A-8907599, WO-A-8911279, US-A-3965101, DE-A-1921049, DE-A-3029871, DE-A-2750288, DE-A-4237768, WO-A-9632384, EP-A-0459830, DE-A-2255525 and EP-A-0114770. Additionally, WO-A-9639400 discloses pyrimidine derivatives that are CRF receptor antagonists. Other pyrimidine derivatives are described in Mariella *et al.*, *J. Org. Chem.*, 25, 647-648 (1960); Zagulyaeva *et al.*, *Izv. Sib. Otd. Akad. Nauk SSSR, Ser. Khim. Nauk*, 4, 27-31 (1990); Essawy *et al.*, *Egypt. J. Chem.*, 37(4), 423-31 (1994); U.S. Patents Nos. 4,543,248, 4,619,933, 4,665,077, 5,002,951, 5,147,876 and 5,223,505, and European Patent Publication No. [EP] 459 830; EP-A-0210044; A-0521471.

One aspect of the invention concerns compounds represented by formula I:



I

wherein:

R^1 is hydrogen, alkyl, hydroxyalkyl, cycloalkyl, cycloalkyl lower alkyl, alkenyl, thioalkyl, halo, fluoroalkyl, optionally substituted phenyl lower alkyl, $-NR^6R^7$, $-CO_2R^8$, $-O(CH_2)_nR^9$, in which

n is 1, 2, or 3;

R^6 and R^7 are independently hydrogen or lower alkyl;

R^8 is hydrogen or lower alkyl; and

AMENDED SHEET

REPLACEMENT SHEET
26 MAR 1999

R^9 is hydrogen, lower alkyl, hydroxy, hydroxy lower alkyl, lower alkenyl, or lower alkoxy;

R^2 is hydrogen, lower alkyl, lower alkoxy, halo, or lower fluoroalkyl;

R^3 is optionally substituted aryl other than pyridyl, thienyl, or furanyl;

R^4 is hydrogen, lower alkyl, optionally substituted phenyl-lower alkyl, hydroxy lower alkyl, acyl, or $-(CH_2)_mNR^6R^7$; in which

m is an integer of 1-6; and

R^6 and R^7 are hydrogen or lower alkyl; and

R^5 is hydrogen or lower alkyl;

provided that:

(i) when R^3 is naphthyl, indol-1-yl, or 2,3-dihydroindol-1-yl, and R^2, R^4 and R^5 are all hydrogen, R^1 is not methyl;

(ii) when R^3 is phenyl or naphthyl, R^1 is not $-NR^6R^7$;

(iii) when R^3 is phenyl, R^2 is not lower alkoxy, and R^1 and R^2 are not halo;

(iv) when R^3 is phenyl and R^1 is H, R^2 is not methyl; and

(v) when R^3 is 1,2,3,4-tetrahydroquinolinyl, R^4 and R^5 are hydrogen;

(vi) when R^3 is phenyl, substituted by methyl, methoxy or halo, R^4 and/or R^5 are hydrogen;

(vii) when R^3 is thiophen, R^1 is not C_1-C_6-alkyl or hydroxy;

or a pharmaceutically acceptable salt or N-oxide thereof.

AMENDED SHEET

REPLACEMENT SHEET
26 MAR 1999

REPLACEMENT SHEET

4-amino-4-(6-methoxy-3,4-dihydro-2H-quinolin-1-yl)-6-trifluoromethylpyrimidine, m.p. 175.6-177.5°C;

2-amino-4-(3,4-dihydro-2H-quinolin-1-yl)-6-ethylpyrimidine, m.p. 141.4-142.1°C;

2-amino-6-methyl-4-(6-methyl-3,4-dihydro-2H-quinolin-1-yl)-pyrimidine, m.p. 170.6-171.4°C;

2-amino-4-(3,4-dihydro-2H-quinolin-1-yl)-6-trifluoromethylpyrimidine, m.p. 162-164°C;

2-amino-4-(6-fluoro-2-methyl-3,4-dihydro-2H-quinolin-1-yl)-6-methylpyrimidine, m.p. 154.9-155.6°C;

4-(3,4-dihydro-2H-quinolin-1-yl)-2-(methylamino)-pyrimidine ;

[2-(3,4-dihydro-2H-quinolin-1-yl)-pyrimidin-4-yl]methylamine;

2-amino-6-methyl-4-(2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-pyrimidine, m.p. 182.6-184.2°C;

2-amino-4-(2,3-dihydro-benzo[1,4]oxazin-4-yl)-6-methylpyrimidine, m.p. 177.7-178.5°C;

2-amino-4-(2-methyl-2,3-dihydro-indol-1-yl)-6-methylpyrimidine, m.p. 182.9-183.4°C;

2-amino-4-(3,4-dihydro-2H-quinolin-1-yl)-6-methylpyrimidine hydrochloride, m.p. 261.5-262.3°C; and

2-amino-4-(3,4-dihydro-1H-isoquinolin-2-yl)-6-methylpyrimidine, m.p. 142.2-143.3°C.

C. Preparation of I where R^1 is Chloro, R^2 is Hydrogen, R^3 is 3,4-Dihydro-2H-Quinolin-1-yl, and R^4 and R^5 are Hydrogen


1,2,3,4,-tetrahydroquinoline (2.66 g, 20 mmol) and 2-amino-4,6-dichloropyrimidine (3.30 g, 20 mmol) were dissolved in 10 ml of N,N-dimethylformamide (DMF), and the entire solution was heated to 70-90°C for 24 hours. DMF was

AMENDED SHEET

REPLACEMENT SHEET
26 MAR 1999

CLAIMS

1. A compound of the formula I:



wherein said compound is a 5-HT_{2B} receptor antagonist, and further wherein:

R^1 is hydrogen, C_1-C_{12}-alkyl, hydroxy-C_1-C_{12}-alkyl, C_3-C_8-cycloalkyl, C_3-C_8-cycloalkyl-C_1-C_{12}- alkyl, C_2-C_{12}-alkenyl, C_1-C_6-thioalkyl, halo, fluoro-C_1-C_{12}-alkyl, phenyl-C_1-C_6-alkyl, optionally substituted by C_1-C_6-alkyl, C_1-C_6-alkoxy, hydroxy, nitro, C_1-C_6-fluoroalkyl and halo; $-NR^6R^7$, $-CO_2R^8$ or $-O(CH_2)_nR^9$, in which

n is 1, 2, or 3;

R^6 and R^7 are independently hydrogen or C_1-C_6-alkyl;

R^8 is hydrogen or C_1-C_6-alkyl; and

R^9 is hydrogen, C_1-C_6-alkyl, hydroxy, hydroxy-C_1-C_6-alkyl, C_2-C_{12}-alkenyl, or C_1-C_6-alkoxy;

R^2 is hydrogen, C_1-C_6-alkyl, halo, or C_1-C_6-fluoroalkyl;

R^3 is phenyl, thiophene, naphthalene, anthracene, phenantrene, quinoline, isoquinoline, 1,2,3,4-tetrahydroisoquinoline, indole, 2,3-dihydroindole, 1H-benzo[1,4]oxazine, 3,4-dihydro-2H- benzo[1,4]oxazine, ; 1H-3Hbenzo[de]isochromene, 6,7,8,9-tetrahydro-5-oxa-9-benzocycloheptane, 2,3-dihydro-1,4-benzodioxane, optionally substituted by C_1-C_6-alkyl, C_1-C_6-alkoxy, hydroxy, nitro, C_1-C_6-fluoroalkyl and halo;


R^4 is hydrogen, C_1-C_6-alkyl, phenyl-C_1-C_6-alkyl, optionally substituted by C_1-C_6-alkyl, C_1-C_6-alkoxy, hydroxy, nitro, C_1-C_6-fluoroalkyl and halo; hydroxy-C_1-C_6-alkyl, $-C(O)$-C_1-C_6-alkyl, or $-(CH_2)_mNR^6R^7$; in which

m is an integer of 1-6; and

R^6 and R^7 are hydrogen or C_1-C_6-alkyl; and

REPLACEMENT SHEET

26 MAR 1999



R^5 is hydrogen or C_1-C_6-alkyl;

provided that:

(i) when R^3 is naphthyl, indol-1-yl, or 2,3- dihydroindol-1-yl, and R^2, R^4 and R^5 are all hydrogen, R^1 is not methyl;

(ii) when R^3 is phenyl or naphthyl, R^1 is not $-NR^6R^7$;

(iii) when R^3 is phenyl, R^2 is not C_1-C_6-alkoxy, and R^1 and R^2 are not halo;

(iv) when R^3 is phenyl and R^1 is H, R^2 is not methyl;

(v) when R^3 is 1,2,3,4-tetrahydroquinolinyl, R^4 and R^5 are hydrogen;

(vi) when R^3 is phenyl, substituted by methyl, methoxy or halo, R^4 and/or R^5 are hydrogen;

(vii) when R^3 is thiophen, R^1 is not C_1-C_6-alkyl or hydroxy;

or a pharmaceutically acceptable salt or N-oxide thereof.

2. The compound of Claim 1, wherein R^4 and R^5 are hydrogen or C_1-C_6-alkyl.

3. The compound of Claim 2, wherein R^1 is C_1-C_6-alkyl, fluoroC_1-C_6-alkyl, or hydroxy-C_1-C_6-alkyl, and R^3 is 1-naphthyl, optionally substituted by C_1-C_6-alkyl, C_1-C_6-alkoxy, hydroxy, nitro, C_1-C_6-fluoroalkyl and halo; or a pharmaceutically acceptable salt or N-oxide thereof.

4. The compound of Claim 3, wherein R^1 is methyl, R^2, R^4, and R^5 are hydrogen, and R^3 is 2- methylnaphth-1-yl, namely 2-amino-4-(2-methylnaphth-1-yl)-6-methylpyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

5. The compound of Claim 3, wherein R^1 is isopropyl, R^2, R^4, and R^5 are hydrogen, and R^3 is 4- fluoronaphth-1-yl, namely 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropyl-pyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

6. The compound of Claim 5, wherein the N-oxide is at the 1-position, namely 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-l-N-oxide.

7. The compound of Claim 3, wherein R^1 is 1-fluoro-1-methylethyl, R^2, R^4, and R^5 are hydrogen, and R^3 is 4-fluoronaphth-1-yl,

namely 2-amino-4-(4-fluoronaphth-1-yl)-6-(1-fluoro-l-methylethyl)-pyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

8. The compound of Claim 3, wherein R^1 is 1- hydroxy-1-methylethyl, R^2, R^4, and R^5 are hydrogen, and R^3 is 4-fluoronaphth-1-yl, namely 2-amino-4-(4-fluoronaphth-1-yl)-6-(1-hydroxy-l-methylethyl)-pyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

9. The compound of Claim 3, wherein R^1 is 1- fluoro-1-methylethyl, R^2, R^4, and R^5 are hydrogen, and R^3 is 4,6-difluoronaphth-1-yl, namely 2-amino-4-(4,6-difluoronaphth-l-yl)-6-(l-fluoro-l-methylethyl)-pyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

10. The compound of Claim 3, wherein R^1 is isopropyl, R^2 and R^4 are hydrogen, R^5 is methyl, and R^3 is 4-fluoronaphth-1-yl, namely 2-methylamino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

11. The compound of Claim 3, wherein R^1 is 2- methylpropyl, R^2, R^4, and R^5 are hydrogen, and R^3 is 4- fluoronaphth-1-yl, namely 2-amino-4-(4-fluoronaphth-1-yl)-6-(2-methylpropyl)-pyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

12. The compound of Claim 3, wherein R^1 is tert-butyl, R^2, R^4, and R^5 are hydrogen, and R^3 is 4- fluoronaphth-1-yl, namely 2-amino-6-(tert-butyl)-4-(4-fluoronaphth-1-yl)-pyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

13. The compound of Claim 2, wherein R^1 is lower alkyl and R^3 is optionally substituted indole as claimed in claim 1, or a pharmaceutically acceptable salt or N-oxide thereof.

14. The compound of Claim 13, wherein R^1 is methyl and R^2, R^4 and R^5 are hydrogen, and R^3 is indol-4- yl, namely 2-amino-4-(1H-indol-4-yl)-6-methylpyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

15. 2-amino-4-(6-methylacenaphten-5-yl)-6-methyl-pyrimidine;
2-amino-4-(acenaphten-5-yl)-6-isopropyl-pyrimidine;

2-amino-4-(acenaphten-5-yl)-6-methyl-pyrimidine;

6-(3,4-dihydro-2H-quinolin-1-yl)-9H-purin-2-ylamine;

2-amino-5-(6-methyl-4-naphth-1-yl)-pyrimidin-2-ylamino)pentanoic acid;

4-(4-fluoronaphth-1-yl)-6-isopropyl-2(piperazin-1-yl)-pyrimidine fumarate;

4-(4-fluoronaphth-1-yl)-6-isopropyl-2-(piperidin-1-yl)-pyrimidine;

4-(4-fluoronaphth-1-yl)-6-isopropyl-2-morpholino-pyrimidine;


4-(4-fluoronaphth-1-yl)-2-(tetrahydro-2-furyl)methyl-amino-6-isopropyl-pyrimidine;

4-(4-fluoronaphth-1-yl)-2-(2-hydroxyethoxy)ethylamino-6-isopropyl-pyrimidine hydrobromide;

4-(4-fluoronaphth-1-yl)-6-isopropyl-2-phenylureidopyrimidine.


16. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of Claims 1 to 15 in admixture with one or more pharmaceutically acceptable non-toxic carriers.

17. A process for preparing a compound of the formula I according to claim 1, or a pharmaceutically acceptable salt or N-oxide thereof; which process comprises reacting a compound of formula (4)



with a boronic acid derivative of formula (5), i.e., $R^3B(OR^{11})_2$ to form a compound of formula I, where R^1, R^2 and R^3 are as defined for formula I, R^4 and R^5 are hydrogen or lower alkyl and R^{11} is H or methyl.

18. A process for preparing a compound of the formula I according to claim 1, comprising of reacting a compound of the formula (6)



with a secondary amine of formula NHR^4R^5 to form a compound of formula I, where R^1, R^2, R^3, R^4 and R^5 are as defined for formula I.

19. A process described in claims 17 or 18 further comprising reacting a compound of formula I with an oxidizing agent to give an N-oxide of a compound of formula I.

20. A process described in claim 17 or 18 further comprising reacting a compound of formula I with a strong acid to give a pharmaceutically acceptable salt of a compound of formula I.

21. A process described in claim 19 further comprising reacting an N-oxide of a compound of formula I where R^1 is alkyl with a carboxylic anhydride to give a compound of formula I where R^1 is hydroxyalkyl or alkenyl; optionally followed by reacting a compound of formula I with a strong acid to give a pharmaceutically acceptable salt of a compound of formula I.

22. A compound as claimed in any one of claims 1 to 15 for use as a therapeutic agent.

23. The use of a compound as claimed in any one of claims 1 to 15 for the preparation of a medicament for the treatment of a disease state selected from the group:

generalized anxiety disorder, panic disorder, obsessive compulsive disorder, alcoholism, depression, migraine, hypertension, sleep disorders, anorexia nervosa, and priapism.